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Human papillomavirus (HPV) infection causes wide range of infections in 
human beings resulting in 100% of cervical cancers and other anogential and 
oropharyngeal cancers. HPV protein E2 plays a vital role in subsequent 
productive and persistent viral infections; HPV E2 protein being a multi 
functional protein binds to several cellular proteins involved in viral entry 
pathways and seems to have a role in modulating intracellular trafficking. 
Previous work in the Parish lab has isolated an interaction between HPV16 
E2 and Rint-1 and hypothesized that the association of HPV E2 with 
membrane associated protein Rint-1 is a part of a novel mechanism in which 
HPV modulates sub-cellular trafficking during HPV infection. The aim of this 
project is to further investigate the interaction between Rint-1 and HPV E2 
and we successfully characterised the functional interaction between Rint-1 
and HPV16 E2 in vivo and from the results obtained, we confirmed that Rint-1 
interacts with N-terminus of E2. We also tried to analyse why Rint-1 is 
interacting with E2 in vivo but not in vitro with phosphatase treated IP. We also 
determined the localisation of HPV16 E2 protein and Rint-1 protein in sub-
cellular elements by sub-cellular fractionation and confirmed that Rint-1 and 
E2 together localise in cytoskeletal fraction. We also tried to analyse the 
localisation of HPV16 E2 following siRNA mediated depletion of Rint-1 by 
Knockdown experiment. From this work, we can speculate that associations 
of E2 with Rint-1will have a role in early stages of HPV infection. 
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Human papillomavirus (HPVs) are small double stranded DNA viruses which 
are non-enveloped with icasohedral symmetry and belong to family papilloma 
viridae. It was in the 1970’s that human papillomaviruses were identified as 
the causative agents of warts (benign skin lesions) in humans and mammals 
(Bernard, 2005). They are categorized as a diverse group of viruses which 
infect different amniotes (mammalian species, reptiles, turtles and also birds) 
(de Villiers et al., 2004). The advancement in molecular biology techniques in 
1980’s made it possible to detect numerous human papillomavirus types in 
malignant and benign mucosal cells such as cervical cancer cells and many 
other laryngeal cells and genital warts (Mammas et al., 2014) and (de Villiers 
et al., 2004) . The International Committee on Taxonomy of Viruses (ICTV) 
data shows more than 200 types of HPV are currently classified, of which 
about 150 HPV types have been isolated and sequenced (de Villiers et al., 
2004, Mammas et al., 2014, Doorbar et al., 2012). The phylogenetic analysis 
and advancement of technical approaches has changed the description of 
HPVs several times. Currently, to define an HPV type as a new type, there 
should be a minimum of 10% dissimilarity of the L1 gene sequence with other 
known HPV types (Bernard, 2005).  
 
 
       History: 
  
In the late 1950s, the discovery of electron microscopy made it possible to 
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observe lots of viruses and as a result of those observations and basic nucleic 
acid sequence study, both papillomaviruses and polyomaviruses were 
discovered and categorized as similar type of viruses and kept in a common 
family called papovaviridae (Bernard, 2005). As it is a known fact that the 
taxonomic classification must be based on natural existence, the ICTV, 
concluded that these two viruses belong to two separate families and since 
then papillomaviruses have been placed in the family papillomaviridae and 





Based upon the specific characteristics of genome organization, phylogenic 
similarities and biological variance, HPVs are classified in to 5 generas like 
Alpha, Beta, Gamma, Mu and Nu-papilloma viruses (de Villiers et al., 2004). 
All of the genitally transmitted viruses are in the Alpha genus; the major 
sexually transmitted viruses from this group are HPV-6, HPV-11, HPV-16 and 
HPV-18 (Doorbar et al., 2012, Bernard, 2005). Approximately 1% of the 
population who are sexually active are infected with HPV-6 and HPV-11 
through oral and sexual routes causing benign lesions (Mammas et al., 2014). 
The major threat of cancers are from  the virus types HPV-16 and HPV-18 
from genus alpha, which cause some mucosal lesions that may convert in to 
high risk cancers such as cervical cancers (Mammas et al., 2014, Bernard, 
2005). The Beta papillomaviruses like HPV5 cause skin cancers in immuno 
suppressed patients or people with genetic defects where as the Gamma 
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papillomaviruses e.g. HPV4 causes small skin warts, the clinical results of this 
sometimes mislead with the results of alpha papilloma virus HPV2 (de Villiers 
et al., 2004, Doorbar et al., 2012). The rest of the human papillomaviruses are 
placed in genera’s Mu and Nu, causing general warts in the human population 
(Doorbar et al., 2012, Mammas et al., 2014). The five genera of HPVs 
genomic diversity and its host cell interactions leading to different clinical 
manifestations are shown in the figure 1. 
 
 
Figure no.1: Different HPV genera and their clinical manifestations. source: 
“Genomic diversity of human papillomaviruses and clinical manifestations: An 
overview in adulthood and childhood” figure taken from (Mammas et al., 
2014). 
 
Of the alpha HPVs, HPV16 and HPV18 are studied the most due to their 
medical and biological importance as they account for more than 70% of the 
cervical, vaginal and anal cancers (Doorbar et al., 2012).  
 




The major mode of HPV transmission is sexual transmission and skin to skin 
contact (Baussano et al., 2010). And there could be chances of vertical 
transmission of oncogenic HPV from infected mother to foetus through 
placenta which is yet to be explored (Porterfield, 2011). The latency period is 
highly variable; from younger women to older women of different age groups 






















Figure no.2: showing the arrangement of early (E) genes, capsid (L1 
and L2) genes and upstream regulatory region (URR) schematically. 
Figure source: “HPV in the etiology of human cancer” figure taken from 




As shown in figure no.2, the HPV genome is an approximately 8000 base 
pairs (bp) circular DNA molecule that is packaged inside the capsid proteins 
L1 and L2. The genome consists of six early proteins E1, E2, E4, E5, E6 and 
E7 which facilitate in the replication and assembly of the viral genome inside 
the infected cell. The upstream regulatory region (URR) of about 1000bp is 
involved in viral gene regulation, genome replication and finally assembling 




HPV16 Virus Life Cycle: 
 
 
Figure no.3 A): Representation of skin, the patterns of gene expression of 
HPV16 and how the infected cell migrates to epithelial surface. The p97 
promoter directs E6 and E7 gene expression required for S-phase entry and 
in the upper layers of epithelium, due to up-regulation of the p670 promoter, 
E4, E2, E1 and E5 expression increases, which will amplify the viral genome, 
and due to modifications in mRNA splicing, the E4 will remain in the upper 
layers where the capsid proteins L1 and L2 are present. (B) Shows different 
stages of the HPV life cycle from genome maintenance to mature viral 
release. Figure source: “The papillomavirus life cycle, Journal of Clinical 
Virology”. Figure taken from (Doorbar, 2005) 
 
In the life cycle of virus, early stages of infection occur by the infectious 
particle attack on basal layer cells as shown in figure 3. Normally the virus 
enters the stratified epithelium through a break, which may be caused by 
abrasion or certain exposure to trauma. The virus reaches the basal epithelial 
cells and infection is initiated (Doorbar, 2005). Virus attachment to the cells 
takes place through the cell surface receptors (Li M, 1998). The uncoating of 
the virus seems to occur through the disruption of disulphide bonds in the viral 
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capsid, mediating the viral genome entry into the nucleus of the cell (Li M, 
1998). Inside the nucleus of the basal cells, the genome is initially maintained 
at a low copy number for which E1 and E2 protein expression is required 
(Doorbar, 2005, Doorbar et al., 2012).  
After infection, the proliferative phase occurs where the basal cells with viral 
genomes increase in number. The viral genome is maintained from 10 to 200 
copies per cell in the basal layer and to maintain the viral episomes, the early 
proteins (E1, E2, E6 and E7), are expressed at low levels (Doorbar, 2005). 
During the proliferative phase the expressed E6 and E7 proteins work 
together to allow the infected cell to enter S-phase of the cell cycle where the 
viral genome copy number is gradually increased facilitated by the E1 and E2 
proteins (Doorbar, 2005). After viral genome amplification, the HPV life cycle 
completes by the expression of two functional proteins in the more 
superfacular differentiated cells. The two functional proteins are minor coat 
protein L2 and major capsid protein L1 (Doorbar et al., 1997). After the exit of 
cell from cell cycle, the L1 facilitates the self assembly of virus like particles 
with the help of L2 in packaging (Roden et al., 2001). The HPV genome is 
encapsided in a capsid containing 360 L1 protein copies and around 12 L2 
protein copies which are arranged in an icasohedral shell with around 72 
pentameric capsomeres (Modis, 2002). Maturation of the virus takes place on 
the surface of dying skin, for successful completion of this process; the virus 
leaves the infected cell before re-infection. The E4 protein presence which is 
present in bulk amount can enhance the virion release, which can then infect 







The human papillomavirus E2 proteins are highly conserved in different 
human papillomavirus types and are involved in viral gene regulation and viral 
genome replication (Hegde and Androphy, 1998). HPV E2 is approximately 50 
kDa in size and consists of a carboxy-terminal DNA dimerization or DNA 
binding domain (DBD) of 100 amino acids linked to amino-terminal 
transactivation domain (TAD) of 200 amino acids. These two domains are 
linked by a hinge domain (Yaniv, 1988, McBride AA, 1988, McBride et al., 
1988).  X-ray crystallography shows that the TAD is made up of 3 α-helices 
which form a twisted plane (Antson et al., 2000) and the carboxy terminal 
domain forms an anti-parallel β-barrel structure (Dell et al., 2003). The DNA 
binding domain binds to palindromic E2 binding sites on URR of the viral 
genome (12 bp motifs) and this TAD is involved in regulation of transcription 
by complex formation with E1 (Pang and Thierry, 2013). E2 binds to the viral 
helicase E1 on the replication origin and together facilitate viral DNA 







    
  
 
Figure no 4: (A) represents the transactivation domain of HPV16 E2 protein 
and figure (B) represents the dimeric DNA binding domain of HPV18 E2 
bound to DNA. Figure source: “The papillomavirus E2 proteins”. Figure taken 
from (McBride, 2013).  
 
 
E2 Transactivation domain: 
The 200 amino acid TAD folds to form a conserved structural domain with a 
cashew shaped structure (figure 4 A) (Antson et al., 2000). TAD has some 
residues inside it, which are responsible for transcription activation and 
repression and replication. Some residues on the outer convex surface (R37 
and R173) facilitate transcription regulation and some on its concave surface 
(E39) facilitates interaction with E1 proteins and replication (Antson et al., 
2000, McBride, 2013). For maintaining the viral DNA, TAD associates E2 with 
mitotic chromosomes in the dividing cells (Xue et al., 2010, Mohr et al., 1990). 
Mutations in this domain can result in the disruption of viral genome and 
mitotic chromosomes tethering (Mohr et al., 1990). Deletions of this TAD 
prevents association of E2 with mitotic chromatin (McBride, 1998). TAD is 
very sensitive; single point mutations or deletion of few amino acids in this 
domain can prevent the attachment of protein to chromatin and also inhibit 
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replication and transcription. Attachment to chromatin is essential for viral 
genome partitioning (Abroi et al., 2004). 
 
DNA binding and Dimerization domain: 
The 85 to 100 amino acid length DBD binds to specific motifs within the viral 
genome. E2 DBD forms a very stable dimer, which is required for association 
with DNA (figure 4 B) (McBride et al., 1988). The consensus binding motif of 
E2 is defined as ACC(N6)CGGT or ACCG(N4)CGGT and is located in 
upstream regulatory region (URR) (Androphy et al., 1987). This E2 DNA 
binding site bends in a way around the domain facilitating the major grooves 
to interact with the recognition helices (Hegde et al., 1992). The charge on the 
interaction surface of the DNA also facilitates E2 in selecting flexible or non-
flexible targets (Kim et al., 2000). 
 
E2 Hinge region: 
The hinge domain of E2 has no defined structure, but forms a flexible link 
between TAD and DBD. The length of the hinge varies between 
papillomavirus genera but is usually similar within different variants of the 
same genus (Gauthier et al., 1991). The HPV E2 hinge region contains mostly 
proline, threonine, arginine, serine and glycine residues (Winokur and 
McBride, 1992). Though the hinge shows no role in replication or transcription 
functions, it mediates spacing in between the TAD and DBD which helps in 
avoiding steric hindrance in between these two domains (Winokur and 
McBride, 1992). The phosphorylation of the hinge region aids auxillary 
functions such as chromatin binding, intracellular localization and also 
14 
 
maintaining protein stability (Garcia-Alai et al., 2006). Also one of the major 
roles of the hinge region is in interacting with other cellular proteins such as 
TNPO3, SMN1, SRSF7, SRSF2 etc., (Lai et al., 1999). 
 
          E2 expression and binding to the HPV URR: 
E2 binds to consensus sites within the upstream regulatory region (URR) of 
viral DNA and regulates viral DNA transcription and replication. By associating 
with E1, E2 binds to the origin of replication and enhances viral genome 
replication and suppresses the expression of E6 and E7 (Goodwin EC, 1998). 
The number of E2 binding motifs varies in different papillomavirus genera, for 
example the alpha papillomaviruses have four E2 binding motifs with highly 
conserved spacing (McBride, 2013). At the 3' end of the URR, the origin of 
replication is present which is made up of an E1 binding sites adjacent to an 
E2 binding site (Mohr et al., 1990). 
 
E2 Intracellular localization: 
E2 proteins predominantly localize in the nucleus, but can also mediate in 
nuclear and cytoplasmic shuttling (Blachon et al., 2005). The nuclear 
localization signals of certain papillomaviruses are known; one is situated 
within the DBD and other was pointed on TAD (McBride, 1998). These signals 
are transplantable to other proteins (McBride, 1998). The hinge region helps 
binding of E2 to nuclear matrix (Zou et al., 2000). E2 forms nuclear foci in the 
presence of E1 which are thought to be the regions of viral genome replication 
(Fradet-Turcotte et al., 2011). The E2 protein plays an important role in viral 
infection through its association with the minor capsid protein L2, and thereby 
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attaching to ND10 domain of nucleus. This domain is also present on the 
adjacent sites of replication foci shows the nuclear bodies have different roles 
in viral life cycle (Day et al., 2004). 
 
          E2 associated cellular proteins: 
HPV E2 is a multifunctional protein and functions in many diverse aspects of 
the virus life cycle by recruiting cellular proteins (McBride, 2013). These 
cellular proteins have been broadly categorized depending on their role into 
functional groups such as RNA processing, cell cycle regulation, protein 
degradation, nuclear import and apoptosis (McBride, 2013, Radaelli et al., 
2012). Examples for some of the E2 host proteins are TopBP1, ChlR1 and 
Brd4 (Donaldson et al., 2007, Parish et al., 2006, Jang et al., 2009). The 
functional interaction of HPV16 E2 with TopBP1 cellular protein is required for 
the viral DNA replication and genome segregation (Donaldson et al., 2007). In 
the absence of TopBP1, HPV16 E2 is thought to associate with an alternative 
complex of cellular proteins and binds to host chromatin (Donaldson et al., 
2007). E2 binds to ChlR1, a DNA dependent helicase protein which catalyses 
the unwinding of single and double stranded DNA by utilizing the energy 
produced during ATP hydrolysis (Parish et al., 2006). E2 binding to ChlR1 is 
essential for E2 association with mitotic chromosomes and viral genome 
segregation (Parish et al., 2006). In addition to the pathways listed above, 
intracellular trafficking has been suggested to be mediated by interaction of 
E2 with cellular proteins which play a vital role in vesicle mediated transport 
but many of these novel interactions have yet to be characterized (Muller and 
Demeret, 2012). Recent studies in the Parish laboratory have demonstrated 
an interaction between HPV16 E2 and a membrane-associated protein Rint-1 
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(Rad50-interacting protein 1) which functions in retrograde transport between 
donor acceptor compartments, Golgi and endoplasmic reticulum. E2 and Rint-
1 co-localize in cytoplasmic compartment (Parish, unpublished). 
 
Membrane-associated protein Rint-1: 
 
Rint-1 (Rad50-interacting protein 1) (figure 5) is an 87 kDa protein which 
consists of 792 amino acids (Xiao et al., 2001, Lin et al., 2007). Rad50 is a 
member of structural maintenance of chromosomes (SMC) family of proteins 
and was first identified in yeast and given the name based on its role in 
recombinational DNA repair activity (Xiao et al., 2001). Rad50 is involved in 
wide range of cellular activities like telomere maintenance (Kong et al., 2006), 
DNA break repair, meiosis, and cell cycle checkpoint (Xiao et al., 2001) by 
interacting with numerous other cellular proteins. Experimental work 
conducted by Xiao et al., has identified a novel interaction of a 87 KDa protein 
with the carboxy terminal of Rad50 and named it as Rint-1 (Xiao et al., 2001) 
and the interaction of Rint-1 with Rad50 was specifically executed during M 
and S phases of cell cycle and participate in cellular processes like cell cycle 
check point activation control (Xiao et al., 2001). Rint-1 also serves as a 
connecting link between Rb family protein p130 and Rad50 by interacting with p130 
protein at amino acids 358 – 440, which is required for telomere maintenance by 
blocking telomerase independent telomere elongation, therefore deletion of 
either Rint-1 or p130 results in elongated telomeres (Kong et al., 2006). Rint-1 
through its N-terminal region also associates with ZW10 (dynamitin interacting 
protein) (Aoki et al., 2009). ZW10 is located inside Golgi and ER apparatus 
(Arasaki et al., 2006). Together Rint-1 and ZW10 forms complex with syntaxin 
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18 complex which is an ER localized N-ethylmaleimide sensitive factor 
attachment protein receptor (SNARE) and target membrane associated 
receptor (SNAP) complex which mediates an important role in vesicle 
trafficking between ER and Golgi apparatus (Hirose et al., 2004, Aoki et al., 
2009). Deletion of either Rint-1 or ZW10 results in dispersion of Golgi 
structure which suggests that both of these proteins are required for the 
structural maintenance of Golgi (Hirose et al., 2004, Aoki et al., 2009). All 
these data show that Rint-1 is involved in multiple functions such as cell cycle 
progression control, telomere  maintenance and sub-cellular trafficking by 
interacting with other proteins (Xiao et al., 2001, Kong et al., 2006, Aoki et al., 
2009, Hirose et al., 2004). Some reports also suggest that over expression of 
Rint-1 in primary non-transformed cells of murine astrocytes has the ability to 
confer tumorigenicity, hence it is also validated as novel glioblastoma (GBM) 
oncogene (Quayle et al., 2012). 
 
Figure no.5: Structural model of Rint-1 protein. Figure source: “Structural 
analysis of the RZZ complex reveals common ancestry with multisubunit 





Role of Rint-1 in Golgi dynamics and cell cycle progression: 
The Golgi apparatus and endoplasmic reticulum (ER) are required for co-
ordinating protein synthesis through post translational modifications in the ER 
and sorting in the Golgi apparatus. Experimental work conducted by some 
scientists’ shows that deficiency of Rint-1 in cells has a severe effect on the 
Golgi apparatus which impairs the normal function of Golgi apparatus and 
protein sorting (Lin et al., 2007). Rint-1 plays a vital role in anterograde 
transport from ER to Golgi by interacting with other cellular proteins that 
likewise have a role in retrograde transport from Golgi to ER (Hirose et al., 
2004). Rint-1 also serves as scaffold component essential for Golgi structural 
integrity maintenance. Also, in enzymatic reactions of disassembly and 
reassembly of Golgi apparatus, Rint-1 was shown to be an important effector 
of upstream signalling in controlling structural conversion steps (Lin et al., 
2007, Xiao et al., 2001). 
 
         Intracellular trafficking: 
 
All cells are covered with membrane which acts as a barrier between the 
inside of the cell and its outer environment. Cellular processes such as 
respiration and DNA replication takes place within intracellular membrane 
bound compartments. Unlike prokaryotic cells, which have only one plasma 
membrane, eukaryotic cells have additional intracellular membrane bound 
compartments which regulate specific functions such as mitochondria for 
respiration and nucleus for DNA replication. The compartment is widely 
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expanded (approximately 1000 to 10,000 greater in volume) resulting in the 
formation of larger cells and all the cell functions are widely separated 
(Tokarev, 2009). The membrane bound compartments in eukaryotic cells 
interact with the cellular environment by vesicle mediated intracellular 
trafficking which move proteins between intracellular compartments. The 
proteins and lipids are transported between these intracellular compartments 
in cargo-loaded vesicles originating from donor compartments which are 
formed with the help of specific adaptor and coat proteins such as COPI, 
COPII and clathrin. These vesicles are then targeted to acceptor 
compartments, where the vesicles attach with the help of tethers and 
membrane fusion takes place with the help of different SNARE proteins 
(reviewed by (Tokarev, 2009). Two major pathways are involved in shuttling 
materials inward and outward termed exocytic and endocytic pathways, 
respectively. There are many proteins involved in vesicle recognition, 
formation and fusion; these include protein components from the vesicle coat 
and SNAREs. The compartment specific v-SNARE in the transport vesicle 
pairs with complimentary t-SNARE on its target compartment, the stable 
SNARE complex mediates membrane fusion (Tokarev, 2009, Vassilieva and 
Nusrat, 2008). Three different SNARE proteins, syntaxin 18, BNIP1 and p31 
together with the membrane proteins ZW10, Sly1 and Rint-1 form the syntaxin 
18 complex which facilitates vesicle transport. Rint-1 in association with ZW10 
in syntaxin 18 complex plays an important role in vesicle trafficking in between 




Role of HPV16 E2 in association with Rint-1 in sub-
cellular trafficking: 
 
Previous work conducted in the Parish laboratory has shown an interaction 
between HPV16 E2 and Rint-1 in vivo (Wijendra et al., unpublished). HPV16 
E2 binds to Rint-1 between amino acids 220 to 264. HPV16 E2 and Rint-1 co-
localise in the cytoplasmic compartments of transfected cells, which are 
thought to be ER-like structures. E2 is predominantly a nuclear protein with 
very little cytoplasmic localisation (Blachon et al., 2005) whereas Rint-1 
localises to ER-like structures (Parish et al., unpublished). Interestingly, co-
expression of these two proteins resulted in a significant accumulation of both 
proteins in ER-like structures. In addition, it has been also suggested that, 
HPV16 E2 regulates sub-cellular trafficking during HPV infection by 
associating with Rint-1. This was demonstrated using a vesicle trafficking 
experiment in which cells were transfected with GFP-tagged temperature 
sensitive vesicular stomatitis virus (VSVG). When cells are incubated at 40˚C 
for 48 hours, GFP-VSVG is retained in the ER. However, incubation at 32˚C 
results in movement of GFP-VSVG to the Golgi and then to the plasma 
membrane. Expression of HPV16 E2 resulted in a significant delay of vesicle 
movement to the Golgi and also to the plasma membrane, suggesting that E2 










II. Project Aims: 
 
1. Hypothesis: 
 We hypothesize that HPV16 E2 interaction with cellular binding 
protein Rint-1, is important for sub-cellular trafficking during HPV 
infection. 
 
2. Overall aim:  





 Determine the Rint-1 binding site on HPV16 E2 using in vitro 
binding assays. 
 Analyze the interaction of Rint-1 with truncated E2 proteins in 
vivo. 
 Analyze the localization of HPV16 E2 protein and Rint-1 protein 
in sub-cellular elements by sub-cellular fractionation. 
 To determine the localization of HPV16 E2 following siRNA-











C33a derived from cervical carcinoma cell line and U20S derived from human 
osteosarcoma cell lines were cultured and maintained in Dulbecco modified 
Eagle medium (DMEM) with 10% fetal bovine serum. The medium was 
changed every 2/3rd day and the cells were incubated at 37°C and 5% CO2 at 
constant humidity. Once the cells became 90% confluent, they were 
trypsinized with 1ml of trypsin per 10cm dish and once detached, 9ml of fresh 
DMEM was added and the cells were mixed well. 10µl of cell suspension was 
pipetted into a haemocytometer and cells were counted and seeded 




100ml of Luria Broth (LB) supplemented with Ampicillin (100 µg/ml) was 
inoculated with a bacterial colony and incubated at 37°C overnight with 
vigorous shaking at approximately 210rpm. Next day the culture was 
transferred into a centrifuge bottle and the bacterial cells were harvested by 
centrifugation at 6000 xg for 15 minutes at 4°C. The supernatant was 
discarded. Following the Qiagen Maxi prep protocol, the pellet was 
resuspended in 10ml P1 buffer (Qiagen kit) containing RNase A. 10ml of P2 
buffer (Qiagen kit) was then added and mixed by inverting the tubes for 5 to 6 
times. The samples were then incubated at room temperature for 5 minutes. 
10ml of chilled buffer P3 (Qiagen kit) was then added and samples were 
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mixed by inverting the tubes 5 to 6 times. Samples were incubated on ice for 
15 minutes and then centrifuged at 20,000 xg for 30 minutes at 4°C. The 
supernatant containing plasmid DNA was carefully removed and transferred to 
new tubes and centrifuged again at 20,000 xg for 15 minutes at 4°C. The 
supernatant was collected. A Qiagen-tip 500 column was then equilibrated by 
applying 10ml of equilibrium buffer QBT (Qiagen kit) and the column was 
emptied by gravity flow. The supernatant with plasmid DNA was then added 
and allowed to enter the resin by gravity flow. After the supernatant had 
passed through the column, it was washed twice with 30 ml of buffer QC 
(Qiagen kit). After washing, the tip was placed on to a centrifuge tube and the 
DNA eluted with 5ml buffer QF (Qiagen kit). After the elution, the DNA was 
precipitated by adding 10.5 ml of isopropanol, mixed gently and centrifuged at 
15,000 xg for 30 minutes at 4°C. After centrifugation, the supernatant was 
carefully removed and the pellet was washed with 5ml ethanol and 
centrifuged at 15,000 xg for 10 minutes at 4°C. The pellet was air-dried for 10 
minutes and DNA was dissolved in TE buffer (pH 8.0) and the final plasmid 
DNA concentration was determined using a Nanodrop. 
 
In Vitro Binding Assay: 
 
Protein expression and GST pull down: 
 
5 ml of LB containing Ampicillin (100 µg/ml) was inoculated from a glycerol 
stock of E.coli transformed with plasmids that express either GST, GST-E2 
NH (containing the N-terminus and hinge region of HPV 16 E2) and GST-E2 
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HC (containing the hinge region and C-terminus of HPV 16 E2) and incubated 
overnight at 37°C and 210 rpm. The following day, 45 ml of LB was inoculated 
with the starter culture which was incubated at 37°C and 210 rpm until the 
optical density at 600nm (OD600) of the culture was 0.6. Protein expression 
was then induced with 1 mM IPTG and the culture was then incubated for a 
further 4 hours 37°C and 210 rpm. The cultures were then transferred to 50ml 
Falcon tubes and centrifuged at 6000 xg at 4°C for 30 minutes. The bacterial 




The frozen pellet was thawed on ice and resuspended in 2 ml of lysis buffer 
(25 mM Tris-HCl pH 8.0, 250 mM NaCl, 1% lysozyme, 1x protease inhibitors 
and 5mM DTT) and incubated on ice for 30 minutes. The suspension was 
then sonicated at 35% amplitude for 3x 10 seconds with 10 seconds rest on 
ice between each sonication before centrifugation at 20,000 xg, 4°C for 10 
minutes. The lysates were transferred to new tubes and pellet was discarded. 
500 µl of the lysate was added to Eppendorf tubes with 20µl of glutathione 
sepharose resin (resin was washed three times with the lysis buffer without 
DTT, inhibitors or Lysozyme) and nutated in the cold room overnight. The next 
day, the beads were centrifuged at 2000 xg for 2 minutes. The supernatant 
was removed and discarded without disturbing the beads and the beads were 
washed three times in lysis buffer without inhibitors and DTT, after the final 
wash, the supernatant was removed and an equal volume of lysis buffer was 
added to the beads and mixed thoroughly.  20µl suspension was taken in to a 
new tube for separation by SDS-PAGE; 10 µl of 2 x protein dye was added 
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and samples were boiled at 95°C for 10 minutes and used to run on 10% SDS 




After running the samples on SDS-PAGE, the gel was carefully removed from 
the cassette placed in a plastic box and washed with distilled water 5 times. 
The gel was covered with Coomassie stain and placed on a gentle rocker for 
1 hour. After an hour the gel was washed with distilled water and placed in 
distilled water on a gentle rocker for another 1 hour after an hour the water 
was replaced with fresh one and rocked for overnight. Next day the gel was 
imaged and the relative amount of each protein was quantified using a Fusion 
device (Peqlab). 
 
C33a cell transfection: 
  
C33a cells were seeded at 3 X 106 cells per dish and allowed to adhere. 5µg 
of Rint-1 DNA was placed in Eppendorf tubes and to that 500µl of serum free 
DMEM was added and (1:2) ratio X-treme gene was added carefully without 
touching the walls of Eppendorf tubes, mixed gently and incubated at room 
temperature for 15 minutes. After 15 minutes the complex prepared in the 
Eppendorf tubes was added drop wise to the C33a cell dishes. The medium 
was mixed gently by swirling and placed in the incubator at 37°C. Next day 
the old media was replaced with 10 ml of fresh DMEM. After 48 hours of 
transfection the cells were harvested, the old media was removed, washed 
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with PBS and the cells were scraped in 500 µl of chilled PBS, collected in to 
tubes and centrifuged at 1000 xg for 5 minutes, The supernatant was 
removed and pellet was stored at -80°C. The cell pellet was resuspended in 
300µl of IP lysis buffer [Tris (50 mM) pH 7.4, NaCl (100mM), NaF (200mM), 
Triton X-100 (1 %), glycerol (10 %) and distilled water] with inhibitors (1%) and 
DTT (0.1 mM), incubated on ice for 30 minutes, sonicated at 35% amplitude, 
10 seconds on and 10 seconds off for 30 seconds. The samples were 
centrifuged at 10,000 xg at 4°C for 15 minutes and Rint-1 lysate was carefully 
collected and saved on ice. 
 
GST-Pull down Assay continuation: 
 
The purified GST, E2-NH and E2-CH beads and Rint-1 lysates were thawed 
on ice and to approximately 20µl of glutathione resin with bound GST protein, 
100µl of Rint-1 C33a cell lysate and 100µl of IP binding buffer with inhibitors 
and DTT (100 mM) was added. Samples were nutated in the cold room for 2 
hours and centrifuged at 2000 xg, 4°C for 2 minutes. The supernatant was 
discarded and beads were washed three times with wash buffer [Tris (100 
mM) pH 7.4, NaCl (100 mM), NP 40 (1%), KCl (200 mM)]. After the final wash, 
approximately to 20 µl of the beads added 20 µl of wash buffer and 10 µl of 6x 
sample buffer. For the inputs, to 25 µl of untransfected lysate and Rint-1 
lysate, added 5 µl of 6x sample buffer, boiled the samples for 10 minutes and 




SDS-polyacrylamide gel electrophoresis: 
 
The resolving gel mix and stacking gel mix was prepared following the 
standard protocol, the glass plates were arranged and using a glass pipette 
approximately 7 ml of resolving gel mix was added to the level marked, 
isopropanol was added on top to level it up and once the resolving gel was 
set, the isopropanol was removed, rinsed with distilled water and stacking gel 
mix was carefully added. The combs were inserted and allowed to set for 30 
minutes. The gel was placed in the running equipment with 1 X running buffer 
(standard protocol) and the combs were removed and proteins were loaded in 
the wells and initially ran at a voltage 100 V until the samples left the stacking 





The PVDF membrane was soaked for a few seconds in methanol and washed 
with distilled water and equilibrated in 1 X transfer buffer for 5 minutes. The 
proteins on the gel were transferred on to PVDF membrane using a standard 
protocol, in 1 X transfer buffer at 100 V for 1 hour. Once the proteins are 
transferred on to the membrane, they were blocked with 5 % milk in 1 X TBS-
T [Tris buffered saline with Tween 20 (0.1 %)] for 1 hour at room temperature 
with gentle rocking. After blocking, the membrane was incubated in 5% milk in 
TBS-T with primary antibody (Goat Rint-1 (Santa Cruz) 1:1000) for 1 hour at 
room temperature with gentle rocking. The membrane was washed in 1 X 
TBS-T for 5 times with 5 minutes interval and membrane was incubated in 5 
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% milk in TBS-T with secondary antibody (Anti sheep/goat HRP; 1:10,000) for 
1 hour at room temperature and again membrane was washed in 1 X TBS-T 
for 5 times with 5 minutes interval and membrane was placed on a cling film 
and covered with ECL reagent, incubated for 3 minutes and proteins were 
detected by chemiluminescence using Fusion digital imaging system. 
 




C33a cells were seeded (3 x 106) cells per 10 cm dish to carry out the 
transfection. In Eppendorf tubes 5 µg of Rint-1 DNA was taken and to it added 
5 µg of DNA for flag tagged full length E2, E2-NH and E2-CH respectively, 
300 µl of serum free DMEM was added, mixed gently and added X-treme 
gene (2:1) ratio and incubated at room temperature for 20 minutes, after 20 
minutes the complex prepared in the Eppendorf tubes were added drop wise 




The cells were washed with PBS and 500 µl of cold PBS was added to the 
dishes and the cells were scraped and collected in tubes and centrifuged at 
3000 xg for 5 minutes, supernatant was carefully removed without disturbing 






The cell pellet was resuspended in 300 µl of IP lysis buffer [Tris (50 mm) pH 
7.4, NaCl (100mM), NaF (200mM), Triton X (1 %), glycerol (10 %) and 
distilled water.] with inhibitors (1%) and DTT (0.1 mM) and incubated for 30 
minutes at 4°C.  The cells were sonicated twice at 30% amplitude for 10 
seconds and centrifuged at 10,000 xg at 4°C for 10 minutes to remove the cell 




250 µl of IP binding buffer (1:1) ratio was added to 250 µl of lysate [binding 
buffer: Tris (50 mM) pH 7.4, KCl (100mM), EDTA (0.1 M), NP-40 (0.20%), 
Bovine serum albumin (BSA) (0.10%), glycerol (2.50%), DTT (2 mM), 
inhibitors (1 %) and distilled water], to it 2 µl of Flag antibody was added and 
for mock sample mouse IgG was added. 10 µl of Protein A conjugated 
sepharose beads was added and whole complex was nutated in the cold 
room at  4 °C for 2 hours. The beads were washed 3 times with 1 ml IP wash 
buffer [Tris (100 mM) pH 7.4, NaCl (100mM), NP- 40 (0.40 %), DTT (2 mM), 
inhibitors (1%) and distilled water]. After the final wash, 25 µl of IP wash buffer 
was added to approximately 25 µl of beads, and 10 µl of 6 x sample buffer. 
For the input samples, 10 µl of 6 x sample buffer was added to 50 µl of 
untransfected lysate, Rint-1 plus E2 full length, E2-CH and E2-NH lysates. 
The samples were boiled at 95 °C for 10 minutes and separated on an 8 % 
SDS-gel. The proteins on the gel were then transferred on to PVDF 
membrane and blocked in 5 % milk in TBS-T for 1 hour and the milk was 
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replaced with 5 % milk in TBS-T with primary antibody goat Rint-1 (santa 
Cruz) 1:500 for 1 hour at room temperature, washed 5 times in 1 x TBS-T 
followed by incubating in 5 % milk in TBS-T with secondary antibody 
(sheep/goat HRP) 1:10000 for 1 hour and washed the membrane again in 1 x 
TBS-T for 5 times and finally the membrane was covered in ECL  reagent for 
3 minutes and detected using a Fusion digital imaging system.  
 
        Sub-cellular fractionation experiment: 
 
2.5 µg of E2 full length DNA, 2.5 µg of Rint-1 DNA was used and the amount 
of DNA was made up to 5 µg with 2.5 µg of Salmon sperm DNA. In three 
different tubes added E2 DNA and Salmon sperm DNA, Rint-1 DNA and 
salmon sperm DNA and E2 DNA and Rint-1 DNA were added respectively. 
300 µl of serum free DMEM and 10 µl (1:2) of X-treme gene was then added 
and the mixtures incubated at room temperature for 20 minutes. After 
incubation samples were added drop wise to the C33a cell dishes and placed 
in an incubator at 37°C, 5% CO2. The next day the medium was replaced and 
after 48 hours of transfection, the cells were harvested by seeding them at 5 x 
106 cells per set and collected in to 10 ml tubes and centrifuged at 500 g for 5 
minutes, the supernatant was discarded and pellet was resuspended in 5 ml 
of PBS and centrifuged at 500 xg for 5 minutes, supernatant was discarded 
and pellet was resuspended in 500 µl of PBS and transferred to Eppendorf 
tubes and centrifuged in micro centrifuge at 1000 xg for 5 minutes. The 






Fractionation experiment was carried out following a standard Thermo-
scientific protocol. To approximately 20 µl of cell pellet 200 µl of ice cold CEB 
(cytoplasmic extraction buffer) with 2 µl of protease inhibitor was added and 
incubated on ice at 4°C for 10 minutes with gentle mixing with hand. The 
samples were centrifuged at 500 xg for 5 minutes and the cytoplasmic extract 
transferred in to pre chilled tube on ice at 4°C. 200 µl of ice cold MEB 
(membrane extraction buffer) with 2 µl of protease inhibitors was added to the 
cell pellet, the tubes were vortexed for 5 seconds and incubated at 4°C with 
gentle mixing for 10 minutes. The samples were then centrifuged at 3000 xg 
for 5 minutes, and the membrane extract transferred to a pre chilled tube on 
ice at 4°C. 100 µl of ice cold NEB (nuclear extraction buffer) with 1 µl of 
protease inhibitor was added to the cell pellet and vortexed for 15 seconds, 
samples were incubated at 4°C for 30 minutes with gentle mixing, centrifuged 
at 5000 xg for 5 minutes and the supernatant was transferred to a pre chilled 
tube on ice at 4°C. 100 µl of chromatin bound extraction buffer was added to 
the cell pellet (Chromatin bound extraction buffer was prepared with 100 µl of 
room temperature NEB, 5 µl of CaCl2 (100 mM), 3 µl of micrococcal nuclease 
and 1 µl of protease inhibitor), and the samples were vortexed for 15 seconds 
and incubated for 15 minutes RT, vortexed again for 15 seconds and 
centrifuged at 16 000 xg for 5 minutes. The chromatin bound nuclear extract 
was transferred to pre chilled tube and stored on ice at 4°C. 100 µl of room 
temperature PEB (pellet extraction buffer) with 1 µl of protease inhibitor was 
added to the cell pellet which was vortexed for 15 seconds and incubated at 
room temperature for 10 minutes, centrifuged at 16,000 xg for 5 minutes and 
the cytoskeletal extract was transferred to pre chilled tube on ice. To 15 µl of 
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the fractions, added 15 µl of 6x sample buffer boiled the samples for 10 




Oligofectamine was used for the transfection. In 2 tubes 1 ml of serum free 
DMEM was taken and 20 µl of oligofectamine was added. 20 µl of control 
siRNA or Rint-1 siRNA was added to separate tubes and incubated at room 
temperature (RT) for 30 minutes. The transfection mixes were added to 6 cm 
C33a cell dishes drop wise (before adding the dishes were washed with PBS 
and added 1 ml of Serum free DMEM) and the dishes were placed in the 
incubator at 37˚C, 5% CO2 overnight. Next day the serum free DMEM was 
replaced with 4 ml of DMEM with 10% fetal bovine serum and placed again in 
the incubator at 37˚C for 24 hours. The samples were harvested in cold PBS 
and the pellet was placed on ice at 4°C.  The cells were lysed in 300 µl of IP 
lysis buffer with DTT (0.1 mM) and inhibitors (1%) and incubated on ice for 30 
minutes. Samples were sonicated twice at 30% amplitude for 10 seconds and 
centrifuged at 16,000 xg for 5 minutes at 4˚C. The lysate was collected and 




Transfection was carried out as mentioned in the co-immunoprecipitation 
methods using 5 µg of E2 DNA and Rint-1 DNA and X-treme gene (1:2) in 
C33a dishes. The cells were harvested by using 500 µl of cold PBS, 48 hours 
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following transfection. Cell pellet was stored on ice, lysis buffer was prepared 
without phosphatase inhibitors. (NaF and β-glycerophosphate and with added 
protease inhibitors and DTT) and 300 µl added to each cell pellet and 
incubated on ice for 30 minutes, sonicated twice at 30% amplitude for 10 
seconds and centrifuged at 16 000 xg for 5 minutes. The lysate was collected 
and distributed equally in to 4 new tubes, the lysate in one tube was incubated 
on ice and rest of the tubes are Mock phosphatase treated or phosphatase 
treated by adding 2 µl of phosphoserine [P0114 (Sigma)] and incubated at 37 
˚C for 1 hour. After one hour, 30 µl of lysate was used as input and rest of the 
lysate was used to co-immunoprecipitate with HPV 16 sheep E2 antibody 





















1) Characterise Rint-1 expression constructs and 
antibodies: 
 
To work with Rint-1 protein, mainly to check the functional interactions 
of Rint-1 with E2 protein, transfections needed to be performed, for this 
purpose purified plasmid DNA was required. The HA tagged Rint-1 
plasmid DNA was purified by maxi prep (Qiagen). 
 
a) Plasmid DNA purification: 
 
The Rint-1 plasmid DNA was purified for further downstream work. The 
concentration of DNA was determined using a Nano drop to measure 
the absorbance of DNA at 260/280 nm. The DNA concentration was 
1227.4 ng/µl and the 260/280 ratio was 1.92, which indicates there is 
probably some RNA contamination or protein contamination. 
                  The purified DNA was used to transfect both U2OS cells 
and C33a cells to optimise the transfection conditions and check the 
efficiency of transfection. The transfections in U2OS cells did not work 
well but it worked efficiently in C33a cells. So, this Rint-1 lysate was 
used to characterise the efficiency of different Rint-1 antibodies. 
 
b) Testing different Rint-1 antibodies 
 
Western blot with four different primary antibodies; Rabbit 2073 
(1:500), Rabbit 2074 (1:500) [these two are gifts from Androphy lab 
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(USA)], HA mouse (1:500) (Covenance) and goat Rint-1(1:500) (Santa 
Cruz Biotechnologies) and respective secondary antibody (1:10,000); 
anti-Rabbit HRP, anti-mouse HRP and anti-goat HRP (as mentioned in 
materials and methods). The results are presented in figure 1. After 
comparison of all the Rint-1 antibodies used, in figure 1, a, b, c and d, it 
was concluded that Goat Rint-1 antibody was highly specific compared 
with other three. 
 
 
Figure.1: Characterization of different Rint-1 antibodies. Figure 1 a, 
b, c and d shows Rabbit 2073, Rabbit 2074, HA mouse and Goat RInt-
1 western blots respectively and Rint-1 lane shows the presence of 














2) Determine the RInt-1 binding site within HPV16 E2 in vitro. 
 
As per my aim to further characterise the interactions between E2 and Rint-1, 
I tried to determine the Rint-1 binding site on HPV16 E2 using GST-pull down 
an in vitro binding assay. Before proceeding to the pull down step, the 
presence of purified GST proteins was checked by SDS-PAGE and 
coomassie staining. 
a) Coomassie staining 
  
 The amount of protein required for pull down assay was quantified by 
coomassie staining and the results were shown in figure 2.a. The intensity of 
the bands in GST lane, E2NH and E2CH lane shows there is an 
approximately equal amount of each protein in all the lanes. 
 
 
Figure 2.a):  Purification of GST E2 proteins: Coomassie staining 
results. The presence of bands in GST lane, E2NH and E2CH lanes was 
visualised and the amount of protein resin mixture required for GST-pull down 





From the above results, I made sure that there is approximately equal amount 
of each protein and estimated required amount as 20µl. 
 
b) GST- pull down in vitro binding assay  
 
Following the above results, 20 µl of protein-bound resin was incubated with 
100 µl of Rint-1 lysate (method was explained in materials and methods). 
The samples were washed and separated by SDS–PAGE and western 
blotted with goat Rint-1 primary antibody and anti-goat HRP secondary. The 
results in figure 2.b show a representative result of three experimental 
repeats. From figure 2.b, the absence of Rint-1 binding to E2 NH, E2 HC 
and GST lanes in presence of Rint-1 indicates that Rint-1 was not binding to 












                                                                     
 Figure 2.b): GST-pull down in vitro binding assay results. The Rint-1 
western blot results shows at approximately 80 kDa, the presence of Rint-1 
protein was observed in the Rint-1 input samples, but there was no protein 
bands in E2 NH (HPV16 E2 N-terminus), E2 HC (HPV16 E2 C-terminus) and 












3) Analysis of the interaction of Rint-1 with truncated E2 
proteins in vivo. 
 
Because Rint-1 protein was not binding to HPV16 E2 proteins in vitro, the 




Five µg of truncated E2 DNAs with 5 µg of Rint-1 DNA and (1:2) X-treme gene 
was used for transfection in C33a cells. Antibodies raised against Rint-1 and 
HPV E2 were used for immunoprecipitation (materials and methods) and a 
representative result of three experimental repeats was shown in figure 3.1.a. 
The appearance of specific bands at approximately 80kDa indicates Rint-1 
binding to Flag tagged E2 full length and E2 NH and not to E2 HC. However, 
due to the presence of less protein in E2 HC lane in Rint-1 western blot and 
more protein in E2 HC lane in E2 western blots compared with E2 NH lanes in 
both the western blots, it cannot be concluded that the Rint-1 protein was 
binding to N-terminus but not C-terminus. The graphs in figure.3.1.b and c, 
shows the IP proteins and input proteins in X-axis and its percentage of 







    
        A) 
Figure 3.1.a): Co-immunoprecipitation. The Rint-1 and E2 was co-
immunoprecipitated from C33a cell lysate and the immunocomplexes and 
10% inputs were resolved on SDS-PAGE and western blotted by using goat 
Rint-1 primary antibody (1:500) and anti-sheep/goat HRP secondary antibody 
(1:10,000) and for inputs, Flag primary antibody (1:1000) and HPV 16 E2 
primary antibody (1:500) and anti-mouse HRP secondary and anti-sheep HRP 
secondary antibody (1:10,000) respectively. In the Rint-1 western blot, Rint-1 
protein was seen at approximately 80 kDa. In the E2 western blot, E2 FL was 
seen at approximately 55 kDa and E2 NH and E2 CH were seen at 











Figure 3.1.b) and c): Graphical representation of three Co-Ip 
experimental repeats. In figure 4 B) X-axis shows inputs for E2 FL, E2 CH 
and E2 NH and immunoprecipitants of Rint-1 and E2 FL, Rint-1 and E2 CH 
and Rint-1 and E2 NH in Rint-1 and Y-axis shows the percentage of the 
protein in Rint-1 western blot. Figure 4 C) shows inputs, E2 FL, E2 CH and E2 




From the above results, it is difficult to conclude that Rint-1 was binding to one 
domain of E2 more than the other, therefore further optimisation of the 
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conditions by reducing the amount of E2 HC DNA used for transfection. 1 µg 
of E2 HC DNA was used instead of 5 µg and by following the same steps of 
transfection as for the above experiment (method was explained in materials 
and methods section), the experiment was repeated and results are 
presented in figure 3.2.a. The result in 3.2.b and c shows that Rint-1 
associates with the N-terminus but not C-terminus of E2. Yet it cannot be 
concluded from these results that Rint-1 binds to N-terminus but not C-
terminus because there is still less protein in E2 HC lane in Rint-1 western 
























Figure 3.2.a): Co-immunoprecipitation. The Rint-1 and E2 was co-
immunoprecipitated using 5 µg of Rint-1 DNA, 5 µg of E2 FL and E2 NH DNA 
and 1 µg of E2 CH DNA from C33a cell lysate and the immunoprecipitated 
complexes and 10% inputs were resolved on SDS-PAGE and western blotted. 
In the Rint-1 western blot, Rint-1 protein was seen at approximately 80 kDa. 
In the E2 western blot, E2 FL was seen at approximately 55 kDa and E2 NH 






















Figure 3.2.b) and c): Graphical representation of co-ip. In figure 3.2.b) X-
axis shows inputs for E2 FL, E2 CH and E2 NH and immunoprecipitants of 
Rint-1 and E2 FL, Rint-1 and E2 CH and Rint-1 and E2 NH and Y-axis shows 
the percentage of the protein in Rint-1 western blot. Figure 3.2.c) shows 





The conditions of this experiment were further optimised by transfecting the 
C33a cells with 200ng and 500ng of E2 HC DNA with 5 µg of Rint-1 DNA and 
for comparison 5 µg of E2 NH DNA with 5 µg of Rint-1 DNA was transfected 
(as mentioned in Materials and Methods section).  
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b) E2 HC western blots 
 
The samples were separated by SDS-PAGE and western blotted for Rint-1 
and E2 by using (1:500) goat Rint-1 (Santa Cruz Biotechnologies) and (1:500) 
HPV16 sheep E2 primary antibodies and anti-sheep/goat HRP secondary 
antibodies (mentioned in materials and methods) and the results were shown 
in figure 3.3. From the figure, In the Rint-1 western blot, at approximately, 80 
kDa Rint-1 protein was seen in E2 HC lanes (200ng and 500ng DNA) and E2 
NH lane (5 µg DNA). At approximately 15 kDa and 35 kDa, E2 HC and E2 NH 
proteins were seen in Flag western blots. The band intensity in E2 HC 500ng 
lane was similar to E2 NH lane. The β-actin western blot served as a loading 








Figure 3.3): E2 western blot. Figure shows Rint-1 and Flag western blot 
results. Lane 1 was untransfected (UT), lane 2 and 3 are E2 HC 200ng and 
500ng DNA with 5 µg of Rint-1 DNA and lane 4 was 5 µg of E2 NH DNA with 
5 µg of Rint-1 DNA. The presence of Rint-1 protein was confirmed at 80 kDa 
in Rint-1 western blot and at approximately 15 kDa and 35 kDa in flag western 
blot, the presence of E2 HC and E2 NH proteins were confirmed. β -actin 





From the above results, the amount of E2 HC DNA required for co-
immunoprecipitation was optimised as 500ng. The co-immunopecipitation 
experiment was repeated with 500ng of E2 HC DNA instead of 5 µg and rest 
are all the same as above experiment (method explained in materials and 
methods). The results are shown in figure 3.4.a. The absence of 
immunoprecipitated Rint-1 in the E2 HC lane and presence of Rint-1 in the E2 
NH lane confirms that Rint-1 interacts to the N-terminus of E2 but not the C-
terminus. This was further confirmed by the presence of equal intensity of 











Figure 3.4. a): Co-Immunoprecipitation.  The Rint-1 and E2 was co-
immunoprecipitated using 5 µg of Rint-1 DNA, 5 µg of E2 FL and E2 NH DNA 
and 500ng of E2 CH DNA from C33a cell lysate and the immunoprecipitated 
complexes and 10% inputs were resolved on SDS-PAGE and western blotted. 
In the Rint-1 western blot, Rint-1 protein was seen at approximately 80 kDa. 
In the E2 western blot, E2 FL was seen at approximately 55 kDa and E2 NH 










Figure 3.4.b) and c): Graphical representation of co-ip. In figure 4 B) X-
axis shows inputs for E2 FL, E2 CH and E2 NH and immunoprecipitants of 
Rint-1 and E2 FL, Rint-1 and E2 CH and Rint-1 and E2 NH and Y-axis shows 
the percentage of the protein present in Rint-1 western blot. Figure 4 C) 
shows inputs E2 FL, E2 CH and E2 NH in X-axis and its percentage on Y-axis 
in E2 western blot. 
 
From the above results, it was confirmed that Rint-1 protein interacts with N-
terminus of HPV16 E2 protein in vivo. 
 
 
4) Phosphatase Assay: 
   
The data presented so far suggest that Rint-1 was interacting with E2 in vivo 
but not in vitro. So furthermore, I wanted to investigate whether any post-
translational modification for example phosphorylation is required for the 
reason behind the interaction. Therefore, I tried analysing by phosphatase 
treated IP. Five µg of E2 full length DNA with 5 µg of Rint-1 DNA (1:2) X-treme 
gene was used to transfect C33a cells (explained in materials and methods 
section). E2 and Rint-1 lysate was divided in to 3 sets and the 1st set was kept 
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at 4˚C, the 2nd set was mock phosphatase treated and the 3rd set was 
phosphatase treated with lambda phosphatase (as explained in methods) and 
samples were resolved by SDS-PAGE and western blotted (as mentioned in 
materials and methods) the results are presented in figure 4. As shown in 
figure 4, though the experiment seems to have worked, as there is a reduction 
in band intensity in phosphatase treated lane in the inputs, probed with 
phosphothreonine primary antibody there was more Rint-1 co-
immunoprecipitated in the phosphatase treated lane. This phosphatase 
treated IP results suggests that, phosphorylation is not the reason for Rint-1 









Figure 4: Phosphatase treated IP. Figure shows phosphatase IP, Rint-1 and 
E2 western blot results. The Rint-1 and E2 was co-immunoprecipitated using 
5 µg of Rint-1 DNA, 5 µg of E2 FL and E2 NH DNA and 500ng of E2 CH DNA 
from C33a cell lysate and the immunoprecipitated complexes and inputs were 
either phosphatase treated or not phosphatase treated and the samples were 
resolved on SDS-PAGE and western blotted with (1:1000) phospho-threonine 
primary antibody (Cell Signalling antibody #9386) and (1:10,000) anti-mouse 
secondary. The second set was western blotted for Rint-1 using (1:500) goat-
Rint-1 primary, (1:10,000) anti-goat secondary and for E2 using (1:500) TVG 
E2 primary and (1:10,000) anti-mouse HRP secondary antibody.  The results 
shows E2 has been masked by IgG. 
 
From, the above results it was confirmed that phosphorylation was not the 
reason for Rint-1 not binding to E2 in vitro. There could be other post 
translational modifications involved in this such as sumoylation, 
ubiquitination etc.  As Rint-1 protein interaction with HPV16 E2 proteins was 




5) Sub cellular Fractionation: 
 
To confirm that Rint-1 and E2 relocalise to cytoplasmic compartments, I 
analyzed the localization of HPV16 E2 proteins and Rint-1 proteins in sub 
cellular localisation by sub cellular fractionation. 
2.5 µg of E2 (full length DNA), Rint-1 DNA and E2 and Rint-1 DNA was 
transfected into C33a cells and fractionated. The 5 fractions [cytoplasm 
extract (CE), membrane extract (ME), nuclear extract (NE), chromatin bound 
extract (CB) and the pellet extract (PE)] of cells with Rint-1, E2 and E2 and 
Rint-1 co-expressed, were compared and analysed with each other through 
Rint-1 and E2 western blots. For fraction controls, samples were western 
blotted for Grb2 (cytoplasm), Orc2 (nuclear soluble), H3 (chromatin) and 
vimentin (cytoskeletal/pellet) and results were shown in figure 5.a and b.  In 
the E2 alone samples, E2 was mainly localised in the nucleus and also in 
cytoplasam, Rint-1 protein was expressed alone predominantly localised in 
the membrane extract and there is a size shift in the pellet fraction, which 
might indicate post-translational modification. However, Rint-1 co-transfected 
with E2 resulted in a dense accumulation of protein in cytoskeletal/pellet 
fraction in all the three repeats. To prove the amount of protein loaded in the 
wells was not the reason for the dense accumulation of E2 and Rint-1 in the 
pellet fraction, the UT fractions were compared with E2 alone and Rint-1 
alone samples. These samples had very little E2 or Rint-1 in the pellet 
fraction as shown in figure 5.c. This proves E2 and Rint-1 together localise in 
pellet fraction. The standard deviation of three fractionation repeats of E2 



























Figure 5. a, b, c):  5 fractions from cytoplasm (CE), membrane (ME), nuclear 
(NE), chromatin (CB) and cytoskeletal/pellet (PE) of E2, Rint, E2+Rint-1 and 
untransfected (UT) are shown with Rint-1, E2 and control western blots. There 
is a size shift in the Rint-1 pellet fraction in the Rint-1 western blot. Western 
blots were quantified by taking the the 5 fractions of E2, Rint-1 and E2 and 


























Rint-1 protein +/- E2 
 
Figure 5.d) : Standard deviations of three fractionation repeats of E2, 





6) Rint-1 siRNA Knockdown 
 
Although it has been shown previously that E2 and Rint-1 localises in the 
cytoskeletal fraction, we furthermore, wanted to address this by determining 
the localisation of HPV16 E2 following siRNA-mediated depletion of Rint-1. 
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For this, to optimise the amount of Rint-1 siRNA required for the depletion of 
Rint-1, 50nM, 100nM and 200nM of Rint-1 siRNA and 200nM of control siRNA 
were transfected in C33a cells using Oligofectamine reagent  and depletion 
was analised by Rint-1 western blot. β-actin western blot was also carried out 
for a loading control and results were shown in figure 6. From the results, the 
gradual depletion of Rint-1 from 50nM lane to 200nM lane was observed. This 
indicates that siRNA mediated knockdown of Rint-1 was successful and that 
200nM siRNA was optimal and optimised the amount of Rint-1 siRNA required 
for depletion of Rint-1 as 200nM.  
 
Figure 6: Rint-1 siRNA knockdown: C33a cells were transfetced with 
control siRNA 200nM, Rint-1 siRNA 50nM, 100nM and 200nM respectively 
and were analysed by Rint-1 western blotting to evaluate the knockdown. 
Loading control, β-actin western blot results shows the amount of protein 
loaded in all the wells are same. 
 
As the knockdown was successful in C33a cells, to check the localisation of 
HPV16 E2, the siRNA knockdown was repeated in U2OS cells (as they are 
engineered to stably express E2) and E2 localisation determined by 
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immunoflorescence. Unfortunately, the knockdown in U2OS cells was not 
successful, and the immunoflorescence showed negative results in two 
repeats because the U2OS cells were not adequately expressing E2. If the 
experiment worked then it might have made it easier to check the localisation 
of HPV E2 and Rint-1 by immunoflorescence and sub-cellular fractionation. 
However, due to lack of time I could not proceed further with optimising the 






















Human papillomavirus (HPV) causes a wide range of infections in human 
beings resulting in a high percentage of cervical cancers and other anogential 
and oropharyngeal cancers. HPV E2 protein plays a vital role in subsequent 
productive and persistant viral infections (Muller et al., 2012). Most of the 
infections tend to persist with or without immune activation (Doorbar, 2005). 
HPV E2 being a multi functional protein, can interact with numerous other 
cellular proteins involved in  different functions, by interacting with some 
proteins essential for viral transport pathways, HPV E2 might play a vital role 
during early stages of HPV infection. Unexpectedly, HPV E2 protein seems to 
have a role in modulating intracellular trafficking by interacting with cellular 
proteins involved in vesicle-mediated transport, which tends to alter the 
intracellular membrane organelle dynamics and likewise affecting its 
maintenance (Muller et al., 2012). Mostly these associated cellular protein 
targets are concentrated on Golgi apparatus, So Golgi in association with type 
II MHC molecules can act as centre for translocating processed viral antigens 
and there by altering the infected keratinocyte’s antigen presentation (Muller 
et al., 2012). All these reasons show HPV E2 might have the potential to 
target host cell intracellular trafficking pathways by interacting with several 
cellular proteins which function in vesicle mediated transport.  
 
The membrane bound compartments in eukaryotic cells interact with cellular 
environment by vesicle mediated intra-cellular trafficking which aid in the 
transportation of proteins and lipids in between intracellular compartments by 
cargo loaded vesicles originated from donor compartments formed of specific 
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adaptor or coat proteins (COPI, COPII and clathrin), then targeted to adaptor 
compartments where  vesicle attachment takes place through tethers and with 
the involvement of different N-ethylmaleimide sensitive factor attachment 
protein receptor (SNARE) proteins, membrane fusion occurs (Tokarev, 2009) 
and by exocytic pathways and endocytic pathways, shuttling of materials 
takes place. Three different SNARE proteins, BNIP 1, p31 and syntaxin 18 
together with some membrane proteins, ZW10, Rint-1 and Sly1 form the 
syntaxin 18 complex which mediates vesicle transport. Together Rint-1 and 
ZW10 form a complex within the syntaxin 18 complex, it targets membrane 
associated receptor (SNAP) complex by an ER localised SNARE complex, 
which facilitates a vital role in vesicle trafficking between ER and Golgi 
apparatus (Hirose et al., 2004, Aoki et al., 2009). 
 
Rint-1 is a membrane-associated protein that helps to mediate anterograde 
transport from ER to Golgi (Xiao et al., 2001) and regulates retrograde 
transport from the golgi back to the ER by interacting with cellular proteins 
(Arasaki et al., 2006). Deletions of Rint-1 from cells have adverse effects on 
Golgi functions such as protein sorting. 
 
Previously, the Parish group has isolated an interaction between HPV16 E2 
and Rint-1 in vivo and concluded that HPV16 E2 and Rint-1 co-localise in the 
cytoplasmic compartments of transfected cells which resembled ER like 
structures and they hypothesized that the association of HPV E2 with 
membrane associated protein Rint-1 is a part of a novel mechanism in which 
HPV modulates sub-cellular trafficking during HPV infection. 
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In my project, we further characterised the functional interaction between Rint-
1 and HPV16 E2.  In the first instance, we purified the Rint-1 plasmid DNA for 
transfections. U2OS cells (derived from osteosarcoma cell lines) were chosen 
for transfections because they are engineered to express E2. Rint-1 DNA was 
transfected using Lipofectamine reagent, but the transfection didn’t work in 
two repeats, as lipofectamine was killing the cells. Therefore, we tried to 
optimise the transfection conditions, and Rint-1 DNA was transfected again in 
U2OS cells using calcium phosphate precipitation method, though the 
transfection worked this time, the cells were no longer expressing E2. So, we 
were unable to proceed further to check the interaction between Rint-1 and 
E2 using U2OS cells. To further examine the interaction, we transfected the 
Rint-1 DNA in C33a cells (derived from cervical carcinoma cell line) using X-
treme gene and the transfection was successful. To proceed further, the lysate 
was used to test the efficiency of four different Rint-1 antibodies; Rabbit 2074 
and Rabbit 2073, goat Rint-1, and HA which detects the HA epitope on 
exogenously expressed Rint-1, and found that optimised goat Rint-1 antibody 
was the most specific. Furthermore, to determine the Rint-1 binding site on 
HPV16 E2, an in vitro GST pull down binding assay was performed followed 
by western blot for Rint-1. Unfortunately the in vitro assay showed negative 
results in all the three repeats and it was concluded that Rint-1 does not bind 
to HPV16 E2 in vitro. To further examine the interaction, we tried to analyse 
the interaction of Rint-1 with truncated E2 proteins in vivo by co-
immunoprecipitation (Co-IP), for this I transfected Rint-1 DNA and flag tagged 
truncated E2 DNAs in C33a cells and IP with flag antibody and western 
blotted to determine whether E2 truncations associated with Rint-1. Results 
from three repeats confirmed that Rint-1 was interacting with N-terminus of 
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E2. As the HPV E2 TAD, consists of intracellular localisation signals, which 
are transplantable to associated cellular proteins, the association of Rint-1 
with N-terminus of HPV E2 could be the reason behind the involvement of 
HPV in sub-cellular trafficking during HPV infection because Rint-1 proteins 
was known to regulate retrograde transport from Golgi back to ER. 
 
From the immunoprecipitation results, it was confirmed that the Rint-1 protein 
was interacting with the N-terminus of E2 protein. At the same time it raised a 
question, why was Rint-1 was interacting with E2 in vivo but not in vitro? 
There could be several reasons for this, such as post-translational 
modifications of E2, for example phosphorylation. Therefore, we tried to 
analyse this by phosphatase treating the lysate used in the IP, for this 
experiment Rint-1 and E2 were co-transfected and the lysates treated with 
phosphatase before Co-IP. Though the experimental results were not clear, 
the phosphatase treatment appeared to work as there was a reduction in 
phospho-proteins in the phosphatase treated inputs compared with the other 
samples in phospho-threonine western blot. However there was more co-
immunoprecipitated Rint-1 in the phosphatase treated lanes, which suggests 
phosphorylation is not the reason for why Rint-1 protein was not interacting 
with E2 in vitro. There could be other post translational modifications involved 
in this, for example methylation, acetylation, ubiquitination, sumoylation, which 
needed to be explored in future research. E2 proteins are already known to 
have post translational modifications through ubiquitination and sumoylation 
because sumoylation is a post translational modification predominantly seen 
in transcriptional factors and E2 proteins are well known to play a key role in 




 Furthermore, we tried to analyze the localisation of HPV16 E2 protein and 
Rint-1 protein in sub-cellular elements by sub-cellular fractionation, the 5 
fractions [cytoplasm extract (CE), membrane extract (ME), nuclear extract 
(NE), chromatin bound extract (CB) and the pellet extract (PE)] of Rint-1, E2 
and Rint-1 in association with E2 were compared and analysed with each 
other through Rint-1 and E2 western blots and fractions control western blots. 
In the E2 alone fractions, E2 was mainly localised in the nucleus and also in 
cytoplasm. In Rint-1 alone fractions, Rint-1 protein was predominantly 
localised in the membrane element. Rint-1 co-transfected with E2 however 
resulted in a dense accumulation of protein in cytoskeletal/pellet fraction in all 
the three repeats. Previous experimental work conducted in the Parish 
laboratory confirmed HPV E2 and Rint-1 co-localise in cytoplasmic 
compartment of transfected cells and have a role in sub-cellular trafficking 
during HPV infection. Now my experimental work showed together Rint-1 and 
E2 are localised in cytoskeletal element. In my opinion, this might be the 
reason for higher levels of viral Ag transport between nuclear periphery and 
the host cell which can regulate nuclear localisation of cellular proteins. In 
future, experimental work should be done to conclude what role this could 
play in HPV infection. 
   
Later on, we tried to determine the localisation of HPV16 E2 following siRNA 
mediated depletion of Rint-1. We optimised the amount of siRNA required for 
Rint-1 depletion as 200nM and the knockdown was successful in C33a cells.  
As the knockdown was optimised in C33a cells, to determine the localisation 
of HPV16 E2 following siRNA mediated depletion of Rint-1, transfection of 
63 
 
Rint-1 siRNA in U2OS cells was required (as U2OS cells express E2) but my 
previous transfections in U2OS cells was not successful, so we tried 
transfecting Rint-1 siRNA in new clone of U2OS cells (clone F) to check the 
knockdown and to proceed with immunoflouresence to see the localisation of 
E2 in Rint-1 depleted cells, Unfortunately the siRNA knockdown was not 
successful in U2OS cells and these cells were also not expressing E2 as a 
result of which localisation of E2 and Rint-1 was not visualised in 
immunoflouresence experiment. Due to lack of time repeating this knockdown 
by optimising the conditions and trying of new clones of U2OS cells was not 
possible but in future research someone needs to optimise these conditions 
and repeat this experiment to determine the localisation of HPV16 E2 
following siRNA-mediated depletion of Rint-1. Other experiments can also be 
done with Rint-1 siRNA like RT-qPCR and can detect the knock down of 
mRNA. 
 
Inside the cell, proteins are transported by vesicles in between donor and 
acceptor compartments, and through retrograde transport some of the 
vesicles shuttle back to donor compartments. Rint-1 proteins are known to 
regulate retrograde transport and E2 proteins can interact with certain host 
cellular proteins and target the intracellular trafficking. The association of Rint-
1 with E2 could affect the dynamics of intracellular organelles and can be 
involved in viral replication during early stages of viral infection by maintaining 
the viral DNA in between the cells and translocating the viral antigens through 
retrograde transport. From this, we can speculate that association of E2 with 
Rint-1 might have a role during early stages of viral infection by targeting host 
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Adenoviruses are used as a model system to study the transcription of viral 
and cellular genes during viral infection, and dissect the molecular basis of 
cellular transformation. The Adenovirus (Adv) early gene product, 13S E1A 
serves to transactivate viral early genes; the CR3 domain of E1A plays a vital 
role in this process. The aim of this project was to investigate further the role 
of E1A interaction with the cellular histone-directed H3 K4 methyltransferases, 
Set1A and Set1B, in transactivation. We successfully confirmed by reciprocal 
co-immunoprecipitation in HEK 293 cells, the in vivo association of Set1A and 
Set1B with Adv E1A. We also determined by chromatin immunoprecipitation 
that Set1A and Set1B associate with viral early gene promoters in Adv5-
infected cells, suggesting that Set1A and Set1B might be important for 
transactivation function. We also demonstrated that Adv E1A associates with 
functional histone H3- and H4- directed methyltransferase activities in HEK 
293 cells. We also identified a number of, potentially new, E1A-interacting 
proteins by mass spectrometry, of which E1A association with MCM proteins 
was validated in HEK 293 cells. This work has established potential new roles 
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Adenoviruses are small, non-enveloped, linear double-stranded DNA viruses 
with an icosahedral nucleocapsid symmetry belonging to the family 
Adenoviridae  (Rowe et al., 1953). Adenoviridae are classed into five distinct 
genera: Mastadenoviridae, Atadenoviridae, Aviadenoviridae, Siadenoviridae 
and Ichtadenoviridae based on their host range. Adenoviruses infect many 
animals including mammals, birds, reptiles, frogs and fish. They generally 
tend to cause upper respiratory tract infections in humans, but they can also 
cause conjunctivitis, cystitis, gastroenteritis and some rashes etc. Mostly the 
infections persist for long periods, especially in immunocompromised patients. 
Apart from understanding the infectious process, adenoviruses have long 
been used as a model system to study the molecular and cellular biology of 
human cells because they are well characterised, low risk and easy to work 
with. Adenoviruses can also be classified as tumour causing DNA viruses, as 
they induce tumours in experimental animals. Hence, they can serve as good 
models to study and understand the molecular basis of cancer (Turnell, 2008).  
1.1. History: 
In 1953, Wallace Rowe and his colleagues first discovered Adenovirus from 
the adenoid and tonsil tissue of infected children after tonsillectomy, hence the 
name (Rowe et al., 1953). But the role of human Adenovirus and its role in 
cancer came to light after the experimental work by John Trenitin and 
colleagues who investigated the tumourigenic properties of adenovirus as part 
of “The quest for human cancer viruses”. They discovered that human 
Adenovirus (hAdv) type 12 causes cancers, typically sarcomas, when injected 
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into baby hamsters (Trentin et al., 1962). Further studies revealed that 
tumourigenesis was dependent upon virus dose and serotype, as well upon 
host age, host genome and host immunity (reviewed by Gallimore and Turnell, 
2001). 
1.2. Classification: 
According to the Baltimore virus classification system, Adenoviruses are 
classified as group I (ds DNA) viruses. The international committee on 
taxonomy of viruses (ICTV) provided a systematic classification of 
Adenoviruses and kept them in the family Adenoviridae and divided in to 5 
sub-families or genera: Mastadenovirus, Siadenovirus, Atadenovirus, 
Aviadenovirus and Ichtadenovirus (Norrby et al., 1976). The Human 
Adenoviruses A, B, C, D, E and F types are categorised principally due to their 
ability to agglutinate red blood cells, and come under the genus 
Mastadenovirus (masta-, mammal) which consists of at least 51 different 
serotypes. The different adenovirus types have different cellular tropisms and 
can cause different infections, like respiratory disease caused by hAdv-B and 
C serotypes, conjunctivitis caused by hAdV-B and D serotypes, and 
gastroenteritis by hAdv-F serotype. Oncogenicity in rodents is caused by 
serotypes of hAdv-A and B sub-groups where sub-group - A shows higher 
level of oncogenicity and sub-group- B shows moderate level (Norrby et al., 
1976).   
1.3. Genome: 
The Adenovirus genome is a linear, non-segmented, ds DNA virus of 
approximately 35,000 base-pairs in size and lies within a capsid containing 12 
pentons and 240 hexons and additional structural proteins (Cusack, 2005). 
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The terminal ends of the genome have inverted repetition (ITR) sequences 
(100 – 140bp). The origin of replication (ORI) lies in between 36 to 46bp of 
ITRs, and a terminal protein (TP) is attached to each end of the genome. The 
adenovirus genome-encoding genes are divided in to two sets of early gene 
transcripts (E1 – E4) and late gene transcripts (L1 – L5) depending upon their 
expression before, or after, viral DNA replication. E1A and E1B gene products 
are essential for viral replication, E2 proteins are involved in providing 
machinery for transcription of late genes and viral DNA replication. The E3 
proteins are required for modulating the host immune response, whereas the 
E4 proteins are involved in promoting functions like viral DNA replication and 
host protein synthesis shut off, as well as being involved in viral mRNA 
metabolism. The virion consists of 13% of DNA mass and 87% of protein 










Figure 1. A) Structure of the Adenovirus Virion: Model of the adenovirus 
virion showing the knob domain, fibre and penton base, as well as hexon, 
core proteins terminal protein and linear genomic DNA. 
B) Schematic representation of the genome of Ad2/5: The upper panel 
shows the genes expressed during viral infection. The lower panel shows the 
multiple mRNAs of the E1A and E1B transcription units. E represents early 







1.4. Life cycle: 
Adenovirus entry into the host cell is coordinated by receptor-mediated 
endocytosis. The viral fibre proteins associate with known cell surface 
receptors, CD46 for hAdv group-B viruses and CAR (coxsackievirus and 
adenovirus receptor) for the other serotypes; v integrins also facilitate 
adenovirus entry. The virus fibre proteins bind to the cell receptor which 
promotes endocytosis and viral entry. After the successful entry of the virus 
inside the host cell, the capsid components get dissociated and virions are 
released in the cytoplasm. Through cellular microtubules the virus gets entry 
in to nuclear core complex, where the viral DNA is released inside the nucleus 
with the help of several cell signalling factors and activation of protein A kinase 
and also p38 /MAPK cascade (Meier and Greber, 2004). Inside the nucleus 
the viral DNA can dissociate from the core proteins and become associated 
with histone molecules and new virions are produced ultimately through a 
coordinated programme of viral gene expression, viral protein synthesis, viral 
DNA replication and virion assembly (Dery et al., 1987). 
1.5. Replication: 
Adenovirus expresses three proteins that function in viral DNA replication: 
preTerminal Protein (pTP), which acts as a primer for the initiation of DNA 
synthesis; E2 DBP which binds viral genome DNA, and E2 Ad DNA 
polymerase (AdPol) which catalyses nascent viral DNA synthesis. There are 
also a number of cellular proteins that facilitate viral DNA replication. 
Transcription factors NFI and NFIII bind to Ad origins of replication and help 
recruit the pTP-AdPol complex, whilst topoisomerases I and IIA help relax 
supercoiled DNA. These cellular proteins cooperate with viral proteins to 
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promote viral DNA synthesis, where AdPol catalyses the initial covalent 
association of dCMP to a pTP serine residue which then serves as a primer 
for Adpol-mediated viral DNA synthesis via strand displacement (reviewed by 
(Ramachandra M., 1999). 
 
1.6. E1A: 
The adenovirus E1A gene is the first gene to be expressed following virus 
infection (Yousef et al., 2009). E1A is required for viral replication and cellular 
transformation and plays a vital role in transcription activation. There are five 
E1A mRNAs produced: 9S, 10S, 11S, 12S and 13S, formed by means of 
differential splicing. The 12S and 13S mRNAs are transcribed during the early 
stages of viral infection whereas the 9S, 10S and 11S mRNAs are all 
transcribed during the late stage of viral infection, though their function 
remains uncertain -reviewed by (Boulanger and Blair, 1991, Lillie et al., 1987). 
In Adv2 and Adv5, 13S and 12S E1A splice variants encode E1A proteins of 
289 amino acids and 243 amino acids, respectively. 12S and 13S gene 
products both share extensive sequence identity across the entirety of the 
E1A molecule except for the presence of an additional 46 amino acid 
sequence in the 289 R (residue) proteins. This 46 amino acid sequence in 
addition to its adjacent sequences are highly conserved amongst different 
adenovirus serotypes and species and is known as conserved region 3 (CR3). 
CR1, CR2 and CR3, were also identified as regions of high conservation after 
sequencing and characterizing the E1A mRNAs in both infected and 
transformed cells; CR4 was identified much later by comparison of the C-
terminal regions of E1A from different serotypes (Avvakumov et al., 2002). 
Indeed, comparison of the E1A coding region from 15 different adenovirus 
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serotypes that infect human and simian species, identified CR4 in the C-
terminal region of E1A between residues 255 to 288 (Avvakumov et al., 2004). 
E1A is heavily post-translationally modified, principally by phosphorylation 
during infection. The molecular weight of E1A upon SDS-PAGE therefore has 
a large variance in size, between 28 and 58 kDa. Both the 289R and 243R 
E1A proteins play a role in transcription, the larger 289R protein has a role in 
transcriptional activation of cellular and viral genes-CR3 is essential for 
transactivation by E1A. Later experimental work concluded an Auxiliary region 
1 (AR1) acidic region adjacent to CR3 from residues 189–200 is important for 







Figure adopted from Gallimore and Turnell, 2001. 
Figure 2. Diagrammatic representation of AdvE1A conserved regions 
and its associated functional domains and binding proteins: This shows 
the AdvE1A conserved regions and its associated cellular proteins that bind to 







1.6.1. Functions of E1A: 
E1A proteins are involved in large number of biological activities including 
activation and repression of transcription, DNA synthesis, apoptosis, mitosis 
and cellular transformation and immortalization in association with cooperating 
oncogenes such as E1B or p21ras. It is also known to function as an anti-
oncogene during tumourigenesis and is involved in suppressing 
transformation and metastasis. As mentioned earlier, E1A proteins are known 
to function in cellular and viral transcription programmes and as such 
associate with numerous cellular proteins that regulate transcription. 
1.6.2. E1A role in transactivation of cellular and viral genes: 
 The adenovirus genome is packaged in the virion with the help of viral core 
proteins V and VII. During the early stages of viral infection, viral DNA can 
dissociate from the core proteins and the ‘naked’ viral DNA, with the help of 
host cell histone proteins, gets rapidly chromatinized (Dery et al., 1985). 
Transcription is assumed to take place both from core template and cellular 
histone template and E1A is known to activate transcription from different 
cellular and viral genes. This temporal regulation of transcription of adenoviral 
genes by E1A is required for replication and for reprogramming the cell 
transcripts to induce the S-phase entry (Dery et al., 1985). Due to lack of 
sequence specificity, E1A can’t bind DNA directly, for this E1A transactivates 
gene promoters by associating with factors that regulate transcription, like 
ATF-2 and YY1, co-activators like CBP/p300, repressors like pRB, p107 and 
p130, co-repressors like CtBP, the general transcriptional machinery, such as 
TBP and TAFs and nucleosomal remodelling factors like SW1/SNF 
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(Gallimore, 2001, Turnell, 2008). 
1.6.3. CR3-mediated transcription: 
Amongst all the transcription pathways of E1A, transactivation mediated by 
CR3 is very important, as it ultimately promotes viral replication. The CR3 
region of the 13S subunit of E1A can activate transcription of viral genes and 
cellular genes by binding to number of transcription factors and proteins that 
function as components of the transcriptional machinery (Jones, 1995). 
The CR3 region of E1A is involved in interacting with different transcriptional 
factors to enhance their activity; it transactivates different cellular and viral 
promoters by means of protein – protein interactions. Experimental studies 
such as mutational analysis of CR3 showed that between residues 180-188 of 
CR3 in the carboxyl terminal region there is a promoter targeting region which 
interacts with numerous transcription factors and TAFs (TBP associated 
factors). TAFs interact with transcription factor activation surface and can 
serve as multi subunit protein complex components (Pelka et al., 2008, Yousef 
et al., 2009). These interactions ultimately result in localization of E1A to 
target promoters in the viral infected cells (Pelka et al., 2008, Yousef et al., 
2009). The CR3 domain also consists of a zinc finger region from residues 
147 to 177 that is also essential for transactivation. The zinc finger domain is 
important for binding the general transcription machinery like TBP for 
transactivation (Webster, 1991). In addition to TBP, some other cellular 
components like TAFs, and mediator component, Sur2 are also required for 






B)                                            Figure adopted from Geisberg et al., 1994. 
Figure 3. A) Shows the N-terminal region, Zinc finger and C-terminal region of 
CR3 domain of Adv 13S E1A. B) Shows the model for CR3 binding to cellular 
proteins in order to stimulate transcription. 
1.6.4. Role of the 12S E1A gene product in transcription: 
Whereas the large, 13S E1A gene product transactivates viral and cellular 
promoters directly through interaction with promoter-bound transcription 
factors, the smaller, 12S E1A gene product can both activate and repress 
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transcription through interaction with numerous transcriptional regulators 
(Gallimore and Turnell, 2001). For instance, the 243R E1A species interacts 
specifically with the pRB family (pRB, p130 and p107) of transcriptional 
repressors and tumour suppressor proteins through interactions with CR1 and 
CR2 (Figure 2; (Gallimore and Turnell, 2001). E1A association with pRB 
mimics the CDK-dependent phosphorylation of pRB and leads to the 
disruption of pRB-E2F repression complexes on E2F-dependent promoters, 
such that E1A associates with pRB and removes pRB from E2F-regulated 
promoters (reviewed by (Frisch and Mymryk, 2002). This allows for the 
activation of S-Phase genes by the E2F family.  
The N-terminal region and CR1 of E1A interacts specifically with CBP, p300 
and P/CAF histone-directed acetyltransferases through residues in the N-
terminal region and CR1 (Figure 2; Gallimore and Turnell, 2001). Indeed, it 
has been determined that the 12S E1A gene product promotes global histone 
H3 lysine 18 hypoacetylation through interaction with cellular 
acetyltransferases (Horwitz et al., 2008). Interestingly, however, microarray 
studies suggest that E1A causes the global relocalization of CBP/p300 during 
infection to genes that promote cell cycle, inhibit differentiation and inhibit 
antiviral responses and, as such, histone H3 lysine 18 becomes 
hyperacetylated at these sites (Ferrari et al., 2008). Conversely, E1A removes 
pRB from these same promoters to de-repress E2F-dependent transcription 
from these loci. 
Mutational analyses have revealed that the ability of E1A to promote 
quiescent cells to enter S-phase resides in its capacity to interact with 
CBP/p300 or the pRB family of proteins (Jelsma, 1989), whereas the ability of 
E1A to induce mitosis resides in its ability to bind both CBP/p300 and the pRB 
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family of proteins (Jelsma, 1989). As such, the ability of E1A to promote 
cellular transformation is also due to its ability to bind CBP/p300 and the pRB 
family of proteins (Gallimore and Turnell, 2001).  
A role for the C-terminal region of E1A in transcriptional control has also been 
determined. A mutant virus which expresses only exon-2 of E1A activates 
transcription in both human cells and in experimental animals (Mymryk and 
Bayley, 1993). One cellular protein known to interact with the exon-2 gene 
product of E1A is the C-terminal binding protein (CtBP) which has been found 
to function as a transcriptional repressor (Gallimore and Turnell, 2001). E1A 
interaction with CtBP also promotes E1A/E1B transformation, though recent 
evidence suggests that CtBP does not suppress E1A/ras-mediated 
transformation (Cohen et al., 2013).  CtBP interaction with E1A is modulated 
by acetylation (Zhang et al., 2000). CBP/p300 acetylates E1A, adjacent to the 
known CtBP binding site at K-239, and inhibits CtBP association, and 
consequently, gene repression (Zhang et al., 2000). 
1.6.5. Role of the Proteasome in CR3-mediated transcription 
Proteasomes are the protein complexes located inside the nucleus and 
cytoplasm of the cell that function to degrade the damaged or unwanted 
proteins by means of proteolysis. The 26S proteasome is 2.5 – MDa in size 
and consists of at least 31 different subunits which degrade both poly-
ubiquitylated and non-ubiquitylated subunits. This proteasome mediated 
degradation of protein complexes is known to have a role in signal 
transduction, transcription, cell cycle control and apoptosis by modulating the 
regulatory proteins involved in these processes (Ciechanover, 1998). The 
degradation of protein is achieved mainly in two step process, first the target 
protein gets ubiquitylated and then degradation occurs through the 26S 
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proteasome (Ciechanover, 1998). This 26S proteasome is an ATP-dependent 
protease complex which consists of a 20S catalytic core protein and 19S 
regulatory protein complexes. The 19S regulatory complex is a 700 KDa 
protein complex with 20 subunits mainly divided in to base and lid sub-
complexes. The base complex in mammalian cells consists of 6 ATPases (S7, 
S4, S10, S6, S6’ and S8) and 3 non-ATPases (S1, S2 and S5a) and the lid 
complex consists of 8 non – ATPases. These base complex 6 ATPases are 
assembled to form hexameric ring structure which will form a connecting link 
between 19S complex and the 20S proteasome and they together can 
degrade the non-ubiquitylated proteins by ATP-dependent manner. The lid 
complex pair with base 20S proteasome complex for the degradation of 
ubiquitylated target proteins in ATP dependent manner (Voges, 1999).  
It has previously been determined that the N-terminal region of E1A is found 
associated with S8 and S4 ATPases of the 19S regulatory complex subunits 
(Turnell et al., 2000). In the absence of oncogenes, E1A is known to regulate 
the p53 expression and ultimately lead to apoptosis. Mutational studies have 
revealed that the N-terminal region of E1A by interacting with proteasome can 
inhibit the degradation of p53 (Turnell et al., 2000). 
Other work conducted in the Turnell laboratory has found that CR3 of E1A 
binds to proteasomes, and that these interactions are essential for E1A 
transactivation function. Indeed, CR3 associates with 19S ATPase proteins 
independent of 20S (APIS), and also binds 20S proteasomes and 26S 
proteasomes, independently (Rasti et al., 2006). Crucial to the purported role 
of 19S ATPases in CR3 function it was also determined that S8 knockdown, 
reduced adenovirus-mediated early region gene expression, considerably. 
The proteasomal-mediated turnover of E1A was also found to be required to 
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promote CR3-dependent transcriptional activation, such that the E1A degron 
and sequences required for transactivation overlapped. It was also 
determined that E1A and 19S and 20S proteasomes are found associated 
with both viral early promoter, and gene sequences, implicating proteasomes 
in both viral gene initiation and elongation programmes.  
S8-CR3 interactions promote the ability of E1A to induce transactivation of 
viral early promoters in mammalian cells during Adv infection in vivo. 
Chromatin immunoprecipitation experiments conducted in the Turnell 
laboratory have shown that proteasomes associate with Adv early region gene 
promoters and gene sequences.  Indeed, these experiments revealed that 
CR3 association with 20S, 26S and APIS are essential for E1A-dependent 
transactivation of early region genes (Rasti et al., 2006). 
1.7. Histone-directed Methyltransferase activity in gene 
activation and repression: 
The massive genomic information encoded within DNA in the form of linear 
sequences is protected by a shield of histone proteins surrounding the DNA in 
the form of nucleosome, which is a unit of chromatin. The core histones H2A, 
H2B, H3 and H4 are components of the nucleosome. The N-terminus region 
of this histones can extend outside the packed DNA area and the amino acids 
present on the tail of histone will undergo post translational modifications like 
acetylation, phosphorylation, methylation, ubiquitylation etc, and these 
modifications will serve as a platform for transcription factors, DNA binding 
proteins and chromatin remodelers to control and regulate gene expression 
(Gallimore and Turnell 2001). Histone modifications in histone tails are 





1.7.1. SET1:  
SET derived its name from Drosophila suppressor and enhancer genes SU 
(Var), E (Var) and trx. The Set domain consists of Histone-directed (H) 
methyltransferase (HMTase) or lysine-directed methyltransferase (KMTase) 
activity. There are eight classes of KMTase activity identified, KMT-1 to KMT-8. 
SET1 is the first member of the KMT2 class isolated from yeast, and is a part 
of the methyltransferase complex, COMPASS, which functions as a histone-
directed H3 lysine 4 (H3K4) methylase. The size of this SET1 complex is 
approximately 450 KDa. In humans, mixed lineage leukaemia (MLL) gene is 
found to have homology to the Drosophila trx gene and the SET1/COMPASS 
proteins in humans that are homologous to yeast Set1 are Set1A, Set1B, 
MLL1, MLL2, MLL3 and MLL4. Set1A is the first H3K4 methyltransferase to be 
identified which is responsible to promote H3K4 mono-, di- and tri-methylation, 
and facilitate gene transcription (Shilatifard, 2012). All these 
methyltransferases exist as multi protein complexes and have some shared 
subunits like RbBp5, Wdr5, Ash2 and Dpy30 which are common between 
yeast COMPASS and the human MLL/Set1 complex. These complexes are 
broadly involved in the activation of gene expression and gene recombination 
(Lee and Skalnik, 2005); (Shilatifard, 2012). 
Sequencing analysis shows Set1A protein share 39% similarity with an 
unknown Set domain protein, K1AA1076 known as Set1B. Set1B associates 
with all the subunits of Set1A like Rbbp5, Ash2, CFp1, Wdr5 and Wdr82 with 
in the 450 KDa complexes. Experimental analysis has demonstrated that the 
Set1B complex also trimethylates histone H3 at the lysine, K4, residue. Both 
these Set1A and Set1B together will bind to certain set of target genes and 
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play a important role in chromatin structural control and gene expression 























I. Project Aims 
1. Hypothesis: 
 We hypothesize that adenovirus E1A interaction with cellular binding 
proteins, such as the Set1A and Set1B histone-directed methyltransferases, is 
important for adenovirus transactivation function. 
2. Overall aim: 
 To investigate the role of Adenovirus E1A, and cellular Adenovirus 
E1A-binding proteins in viral gene regulation. 
3. Sub-aims: 
 To investigate the roles of 12S and 13S E1A gene products during 
infection. 
 To characterise E1A interactions with cellular proteins in vivo. 
 To investigate E1A association with histone H3- and H4- 
methyltransferases in vivo. 
 To investigate Set1A and Set1B association with Adv early region 
promoters in Adv5-infected cells. 
 To investigate the role of Set1A and Set1B in viral early gene 
expression. 










II. Materials and Methods 
 
1. Cell Biology: 
1.1. Dulbecco Modified Eagles Medium (DMEM):  
Commercially available HEPES-buffered DMEM purchased from Sigma, was 
supplemented with 8 % (v/v) foetal bovine serum (FBS) and 2mM L-glutamine 
(Sigma) and stored at 4˚C before use. 
 
1.2. Phosphate Buffered Saline (PBS):  
Commercially available Dulcecco A (PBS) Tablets (Oxides) were dissolved in 
sterile distilled water (1 tablet/100ml), autoclaved and stored at room 
temperature. PBS tablet consists of 0.8g/L sodium chloride, 0.02g/L 
potassium chloride, 0.115g/L disodium hydrogen phosphate and 0.02g/L 
potassium dihydrogen phosphate (pH 7.4). 
 
1.3. Saline:  
One Saline tablet (Oxides) was dissolved in 0.5 litres of sterile distilled water 
and sterilized by autoclaving and stored at -4˚C. 
 
1.4. Trypsin:  
Commercially available trypsin (1X) was purchased from Sigma, aliquoted in 






1.5. Maintenance of cell lines:  
Ad5 E1-transformed, human embryo kidney (HEK) 293 cells, Ad12 E1-
transformed human embryo retinoblasts (HER2), and human A549 small cell 
lung carcinoma cells were cultured and maintained in HEPES-buffered DMEM 
supplemented with 8% (v/v) FBS and 2mM L-glutamine and the cells were 
incubated at 37°C and 5% CO2 at constant humidity. Once the cells became 
90% confluent, they were washed once with 10ml PBS and treated with 1ml of 
trypsin (1X) per 10cm dish. Once detached, 9ml of fresh DMEM was added 
and the cells were mixed well. Ten µl of cell suspension was pipetted into a 
haemocytometer and cells were counted and seeded accordingly, onto new 
10cm dishes. 
 
1.6. Adenoviral infection:  
A549 cells at approximately 90% confluence were selected for infection. The 
dishes were washed twice with 5ml serum-free DMEM. Adenovirus was 
diluted in serum-free DMEM at a multiplicity of infection (m.o.i.) of 10 particle 
forming units (p.f.u)/cell, unless otherwise stated, and added drop wise to the 
dishes and incubated at 37˚C for 2 hours in a humidified incubator with 5% 
(v/v) CO2. Dishes were rocked gently at 15 minutes intervals to ensure the 
even dispersal of virus. After 2 hours the excess virus was removed carefully 
and the dishes supplemented with 10 ml fresh DMEM containing serum and 







2. Protein Biochemistry: 
2.1. Bradford assay: 
To determine protein concentration, 4 µl of the protein sample was diluted with 
1 ml of Bradford reagent (BioRad). Bovine serum albumin (BSA) 0-30 µg was 
used to generate a calibration curve from which the unknown protein 
concentrations were determined. The absorbance was measured using a 
spectrophotometer at 595 nm against the blank (distilled water). 
 
2.2. Sodium dodecyl sulphate-polyacrylamide gel electrophoresis 
(SDS-PAGE): 
Typically, 50 µg of protein lysate, or immunoprecipitated samples, were 
separated by SDS-PAGE (10 % (w/v) Acrylamide/Bis-acrylamide [37.5:1-
Severn Biotech Ltd], 0.1M Tris-Bicine pH 8.3, 0.1% (v/v) SDS, 0.3% (v/v) 
TEMED (N, N, N’, N’-tetramethyl-ethylenediamine). APS (ammonium 
persulphate) was added to a final concentration of 0.06% (w/v) to initiate 
acrylamide polymerization. Prior to polymerization the gel mixture was poured 
into a gel cassette (Hoefer), and a comb was inserted to create wells for 
loading the samples. The combs were removed after gel polymerized and the 
wells were rinsed with dH2O and placed the cassette in running buffer (Tris-
Bicine (0.1 M), pH 8.3, SDS (0.1% (w/v)). Samples were loaded in the wells 
alongside suitable pre-stained protein standards and run at 10-20mA 
overnight depending on the proteins being investigated. 
 
2.3. Urea-PAGE: 
For immunodetection of adenovirus E1A, immunoprecipitated samples were 
separated by urea-PAGE in the absence of SDS [urea (8 M), Tris (15.2 mM), 
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glycine (96 mM) pH 8.5, 0.3% (v/v) TEMED and 0.06% (w/v) APS]. The gel 
mixture was poured into a urea gel cassette apparatus and levelled with a 
water-saturated Butan-2-ol, which was washed off with distilled water when 
the gel was polymerised. Before running the sample, the gel was pre-run at 25 
mA in urea gel running buffer [Tris (15.2 mM), glycine (96 mM) pH 8.5] for 2 
hours. The samples along with 25 µg of protein lysate input, in equal volumes 
of urea gel sample buffer, were loaded and ran at 15 mA for 4 hours (twice). 
 
2.4. Coomassie staining: 
After running the samples on SDS-PAGE, the gel was carefully removed from 
the cassette and placed in a plastic box and washed with distilled water. The 
gel was covered with 0.1% (w/v) Coomassie brilliant blue R-250 stain (Sigma) 
in methanol/glacial acetic acid/water (4:1:5 v/v) and placed on a gentle rocker 
for 20 minutes and destained again in methanol/glacial acetic acid/water 
(4:1:5 v/v). 
 
2.5. Histone-directed Methyltransferase assay: 
Confluent A549 cell dishes were lysed in Hi Lo buffer, protein concentration 
determined, and lysates incubated with anti-E1A antibodies (20 µg) by rotation 
at 4˚C overnight. The next day 20 µl of packed Protein-G Sephasrose beads 
were added to the mixtures and incubated, by rotation, for an additional 2 
hours at 4˚C. The beads were then washed 4X with Hi Lo buffer. To the beads, 
2µl radioactive-adenosyl-L-[Methyl 3H]-methionine, 2l of 10 mg/ml of core 
histones (H2A, H2B, H3 and H4) and 16 µl of methyl transferase buffer 
(50mM Tris pH 8, 30 mM KCl, 10 mM MgCl2 and 10 mM β-mercaptoethanol) 
were added and samples incubated for 1.5 hours at 30˚C. After this time 
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sample buffer was added and samples were separated by SDS-PAGE. The 
gel was then stained with coomassie, dried and exposed to X-ray film at -
20ºC, and developed as appropriate. 
 
2.6. Mass Spectrometry: 
Adv E1A immunoprecipitates from A549 cells were washed twice with 
detergent free lysis buffer. Proteins were then denatured in 0.5ml 9M 
Urea/50mM ABC (50mM Ammonium Bicarbonate (ABC), and incubated at RT 
for 30 minutes to 1 hour, vortexing occassionally. The beads were then 
pelleted and the supernatant containing the protein was collected. To the 
supernatant, 50 mM DTT (final concentration) was added and incubated at 
56˚C for 30 minutes. 100 mM iodoacetamide (final concentration) was then 
added to the supernatant and incubated in the dark for 30 minutes at room 
temperature. 300 µl of the supernatant was added to the FASP filters (Amicon 
Ultra 30K) and centrifuged at maximum  speed for 10 to 15 minutes (until the 
lysate was reduced to approximately 50 l). The flow through was discarded 
and the remaining lysate was added to the filters and subject to further 
centrifugation. The filters were then washed 4X with 50 mM ABC, whereupon 
the FASP filters were moved to new tubes and resuspended in sequencing 
grade trypsin (1 µg of trypsin per IP), diluted with 50 mM ABC to give a final 
volume of 300 µl. Samples were incubated at 37ºC overnight. The next day 
samples were centrifuged at high speed for 10 to 15 minutes to obtain tryptic 
peptides. Filters were washed once with 300 µl of 50 mM ABC and eluates 





3.1. Harvesting cells for Immunoprecipitation:  
Cells were washed twice with ice-cold isotonic saline solution and lysed with 1 
ml/dish of HiLo salt solution [50mM Tris (pH 7.5), 1% (v/v) NP-40 and 0.825M 
NaCl] at 4˚C for 10 minutes. The cells were harvested and sonicated at 30% 
amplitude, 10 sec on and 10 sec off and then centrifuged at 4˚C for 20 
minutes at 13,000 ×g. The lysate was collected and saved at 4˚C and to it was 
added a primary antibody to precipitate the appropriate immunocomplex 
overnight at 4˚C.  The next day 30 µl of protein G agarose beads (Sigma) 
were added to the immunocomplexes and rotated in the cold room for 2 
hours. Immunocomplexes bound to the beads were then washed 4 times with 
1 ml HiLo buffer. The beads were suspended with either 20 µl of urea sample 
buffer [Tris (18.6 mM), Glycine (115 mM) and bromophenol blue (w/v 0.1%)] 
for running the samples on urea-PAGE, or resuspended in 20 µl of SDS 
sample buffer for running the samples on SDS-PAGE. 
 
3.2. Western blotting: 
Following SDS-PAGE and urea gel-PAGE, the proteins on the gel were 
transferred on to nitrocellulose membrane using a standard protocol. The 
cassette was set up by placing a 3 MM Whatman filter that had been pre-
soaked in transfer buffer (0.05 M Tris, 0.1 M glycine and 20% (v/v) methanol) 
upon a blotting sponge. A nitrocellulose membrane that had also been pre-
wetted in transfer buffer was then placed upon the Whatman paper, after 
which the gel was placed on top of the nitrocellulose membrane, and was 
again overlaid by another sheet of pre-soaked 3 MM Whatman filter paper and 
a blotting sponge in transfer buffer. The cassette was then transferred to the 
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transfer apparatus (Hoefer) filled with transfer buffer and run at 250 mAmps 
for 6 hours. After protein transfer, the membrane was stained with 0.1 (w/v) 
Ponceau S (Sigma) in 3% (w/v) trichloroacetic acid, to visualize proteins. 
Membranes were then washed with 1 X TBS-T [Tris buffered saline with 
Tween 20 (0.1%)] and subsequently blocked in 5 % (w/v) milk in 1 X TBS-T for 
30 minutes. After blocking the membrane was placed in a plastic bag 
containiing 5 % (w/v) milk in 1 X TBS-T with primary antibody at the 
appropriate dilution, and were heat sealed and incubated overnight at 4˚C on 
a gentle rocker. Next day the membrane was washed 3 times with 1 X TBS-T 
and incubated in horseradish peroxide anti-species secondary antibody 
(Dako) for 2 hours on a gentle rocker at room temperature. The membrane 
was then washed 4 times with 1 X TBS-T (at 15 minutes intervals). The 
membrane was then incubated with enhanced chemiluminescence reagent 
(ECL; Millipore) for 1 minute. The membrane was placed on a cling film 
(Saran wrap sheet) exposed to X-ray film sheets (Kodak) for the desired 
period of time depending on the protein (few seconds to a few minutes) and 
the film was then developed in a developer (X-OMAT). 
 
3.3. Chromatin immunoprecipitation (ChIP) assay: 
A549 cells were infected with wild type Adv5 at an m.o.i. of 1 pfu/cell. 16 hours 
post infection the cells were treated with Formaldehyde (final concentration 
1% (v/v)) to cross-link histones to DNA and incubated for 10 minutes at 37˚C. 
Later, the cells were washed twice with 5 ml of ice-cold PBS and harvested in 
1 ml of PBS and centrifuged. The pellet was re-suspended in 0.550ml of SDS 
lysis buffer (50 mM Tris-HCl pH 8.1, 1% (v/v) SDS and 10mM EDTA) and kept 
on ice for 10 minutes. The lysate was then sonicated twice at 30% amplitude, 
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10 seconds, to shear the DNA. 50 µl of the sonicated lysate was taken from 
the supernatant and diluted to make up to 200 µl by lysis buffer and kept as 
input. The remainder of the supernatant was diluted 10 fold with ChIP dilution 
buffer (20 mM Tris-HCl pH 8.1, 1.1% (v/v) Triton X-100, 0.01% (w/v) SDS, 1.2 
mM EDTA and 150 mM NaCl) and pre-cleared with 50 µl of Protein A agarose 
slurry (containing 1mg/ml BSA and 400g/ml Salmon Sperm DNA) for 2 hour 
at 4˚C by gentle agitation. Equal volumes of cleared lysates were incubated 
with the appropriate antibody and mixed by rotation in the cold room at 4˚C 
overnight. To collect the histone/antibody complex, 50 µl of a Protein A 
agarose slurry (containing 1mg/ml BSA and 400g/ml Salmon Sperm DNA) 
was added to the samples and incubated for 2 hours at 4˚C. The beads were 
then washed 3 to 4 times, by gently spinning on a rotating platform, in 1 ml of 
the following buffers; 1 X low salt immune complex wash buffer (20 mM Tris-
HCl pH 8.1, 1% (v/v) Triton X-100, 0.1% (w/v) SDS, 2mM EDTA and 150 mM 
NaCl); 1 X high salt immune complex wash buffer (20 mM Tris-HCl, pH 8.1, 
1% (v/v) Triton X-100, 0.1% (w/v) SDS, 2 mM EDTA and 150 mM NaCl); 1 X 
LiCl immune complex buffer (10 mM Tris-HCl pH 8.1, 1% (v/v) NP40, 0.25 M 
LiCl, 1 mM EDTA and 1% (w/v) sodium deoxycholate) and 2X TE (10 mM Tris-
HCl pH 8.0, and 1 mM EDTA). Protein-DNA complexes were then eluted from 
the Protein A beads using 0.5 ml of freshly prepared elution buffer (0.1 M 
NaHCO3 in 1% (w/v) SDS) by incubation at room temperature for 30 minutes 
with gentle rotation. Eluates were combined and transferred to fresh tubes 
whereupon histone-DNA crosslinks were reversed by the addition of 20l 5M 
NaCl and heating at 65˚C for 4 hours. Input histone-DNA crosslinks were 
reversed by the addition of 8l of 5M NaCl and heating at 65˚C for 4 hours. 
After reversal of cross-links 10 µl of 0.5 M EDTA, 20 µl of 1M Tris-HCl pH 6.5, 
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and 2 µl of 10 mg/ml Proteinase K was added to the eluates and incubated at 
45˚C for 1 hour. Following phenol/chloroform extraction, the DNA was 
recovered and the DNA pellet was visualised by ethanol precipitation and by 
adding 20 µg of glycogen. Later the DNA pellet was washed twice with 70% 
ethanol and air dried, resuspended in 50l sterile water and frozen for PCR. 
 
4. Molecular Biology techniques: 
4.1. Polymerase chain reaction (PCR): 
PCR was performed to amplify DNA following ChIP using 2U Fast-start Taq 
polymerase (Roche) following the manufacturer’s guidelines. A GC-Rich 
solution buffer was used in order to alter the melting nature of DNA and was 
used for templates with high GC-content such as the promoter regions 
amplified here. PCR was performed using a thermal cycler for 10 minutes at 
94˚C for DNA denaturation and 30 cycles DNA amplification (60 sec at 94˚C, 
30 sec at 50˚C and 120 sec at 72˚C). The amplified DNA was separated by 
agarose gel electrophoresis. The oligonucleotides used for amplification were 
as follows: 
E1A promoter: tgacgtagtagtgtggcggaagtgt (Forward-F), 
tataaatacactacacgtcagctga (Reverse- R). E1B promoter: 
gtgtctagagaatgcaatagtagtacggat (F), taaccaagattagcccacggcgcattatat (R). 
E2e promoter: tcatgtagtttattcgggttgagtagtctt (F), 
atactgcgcgctgactcttaaggactagtt (R). E3 promoter: 
tggtgtaccaggaaagtcccgctcccacca (F), caagcgaggagctcaccgactcgtcgttga (R). 





4.2. Agarose Gel electrophoresis: 
DNA fragments were separated upon 0.8% (w/v) agarose (Sigma) in 1X TBE 
(Tris-Borate-EDTA) containing (0.5 µg/ml) ethidium bromide. Samples were 
diluted with 6X gel buffer (30% (v/v) Glycerol (BDH), 0.25% (w/v) 
bromophenol blue (Sigma) and 0.25% (w/v) xylene cyanol FF in sterile 
distilled water) and loaded in the wells. Electrophoresis was carried out at 60 
V in 1X TBE running buffer for 45 minutes and the gel was observed under a 






























1. Investigating the roles of 12S and 13S E1A gene 
products during infection: 
Adenovirus E1A proteins play an important role in transactivation function and 
cell cycle regulation during infection. Adv-regulated transactivation of Adv 
early region gene promoters is dependent on the expression of the 13S E1A 
species, whilst the smaller 12S E1A gene product promotes cell cycle entry 
through binding pRB and CBP/p300. Initial experiments were therefore 
designed to study the differences between 12S and 13S in promoting Adv 
early region gene expression. To do this I infected A549 cells with Adv5 
expressing either 12S-only or 13S-only at 10 pfu/cell and harvested cells at 
4h, 8h, 18h and 24h post infection in UTB buffer, separated proteins on 10% 
SDS-PAGE and Western blotted for E1A, p53, E4Orf6, E4Orf3, E2A and E1B-
55K, as well as loading control, β-actin (Figure 1A). From the results it was 
clear that the expression of, E4Orf6 and E4Orf3, which are required for 
efficient viral DNA replication was wholly dependent upon 13S E1A 
expression, as these proteins were not identified following infection with the 
12S-only virus (Figure 1A). E1B-55K and E2A expression were also largely 
dependent upon 13S E1A expression, but 12S E1A induced their expression 
at considerably reduced levels (Figure 1A). p53 tumour suppressor protein 
levels were stable over this time-course following 13S E1A expression, and 
was increased following 12S E1A expression, presumably as E4Orf6 is not 
expressed (Figure 1A). From the results obtained we confirm earlier studies 
indicating that 13S subunit plays a key role in transactivation, and 12S E1A 
does not play a major role in the transactivation of early region gene 
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promoters. We next optimised the infection conditions for different doses of 
wild type Adv 5 (0.5, 1, 5 and 10 pfu/ cell) for infection of A549 cells and 
harvested infected cells at 24h and 48h post infection in UTB buffer; Western 
blot results are presented in Figure 1B. It can be seen that E1A and E1B-55K 
were detected at all viral doses. There was comparatively more E1A protein at 
24h relative to 48h, consistent with its role in the early phase of infection, 
whereas E1B-55K protein levels were very similar at different moi’s (Figure 
1B). p53 was degraded at all doses of virus, but was more rapidly degraded in 
those cells infected with higher doses of virus (Figure 1B). β-actin western blot 
is shown as loading control. From the results we decided that the optimal 










                    
 
 
Figure 1A. Adv5 12S E1A-only and 13S E1A-only infection of A549 cells. 
 A549 cells were infected with Adv5 12S-only or Adv5 13S-only viruses and 50 
µg of protein from 4hours, 8hours, 18hours and 24hours post-infection was 
separated on 10% SDS-PAGE and Western blotted for E1A, E1B, E2A, p53, 
E4ORF3, E4ORF6 using E1A (primary, M58 (1:2000) and anti-mouse HRP 
secondary (1:2000), E1B-55K (primary, 2A6 (1:2000) and anti-mouse HRP 
secondary (1:2000), E2A (primary, B6-8 (1:1000) and anti-mouse HRP 
secondary (1:2000), p53 (primary DO-1 (1:20) and anti-mouse HRP 
secondary (1:2000), E4Orf3 (primary 6A11, (1:50) and anti-rat HRP secondary 
(1:2000) and E4Orf6 (primary RSA3, (1:20) and anti-mouse HRP secondary 
(1:2000). Proteins ran at approximately 40 kDa, 55 kDa, 11 kDa, 34 kDa and 





Figure 1B. Adv5 wild-type infection of A549 cells.  
A549 cells was infected with Adv wild type at 0.5, 1, 5 and 10 pfu/cell and 
mock without infection and harvested in UTB buffer 24h and 48h post-
infection and the samples were separated on 10% SDS-PAGE and Western 
blotted for E1A, E1B, p53 and actin using primary and secondary antibodies 







2. Characterisation of E1A interactions with cellular 
proteins.  
A. Co-immunoprecipitation of E1A with known binding partners 
To study the cellular functions of E1A, especially to understand the basis of 
E1A dependent transactivation, it is important to characterise the functional 
interactions between E1A and cellular binding-proteins. Therefore, I harvested 
HEK293 lysates in HiLo buffer and performed immunoprecipitation with 
antibodies raised against known E1A-binding partners: CBP an N-terminal 
and CR1 binding protein; TBP, which binds to the N-terminal region and CR3; 
pRb family of proteins (pRb, p107 and p130) which bind to CR1 and CR2; and 
CtBP a C-terminal binding protein (Figure 2A). From the results obtained we 
can conclude that antibodies raised against pRb family proteins pRb, p107 
and p130 co-immunoprecipitate E1A most efficiently, when compared to C-
terminal and N-terminal binding proteins CtBP, CBP and TBP (Figure 2A). The 
association of E1A with pRb family proteins is important for E1A induction of 
cell cycle and cellular transformation, and repression of cellular differentiation. 
It is also evident that CBP bound more efficiently to the 12S E1A species 
(lower band), whilst the particular anti-TBP and anti-CtBP used in this study 





           Figure 2A. Co-precipitation of E1A with known binding partners 
Cellular binding proteins were immunoprecipitated from HEK293 cell lysate 
and normal IgG was used for the negative control. Immunocomplexes were 
isolated on Protein G Agarose beads, and separated along with 10% input 
(positive control) by urea-PAGE (in the absence of SDS) and E1A association 
was analysed using an anti-E1A (M58) primary antibody (1:2000) and anti-
mouse HRP secondary (1:2000). 
 
B. E1A immunoprecipitation of known binding partners in vivo. 
After analysing the E1A binding cellular proteins through immunoprecipitation 
of known binding proteins followed by an E1A western blot, I proceeded to 
characterise further the functional interactions of E1A with cellular binding 
proteins through immunoprecipitation of E1A from HEK293 lysates followed by 
Western blotting with known E1A-binding partners (Figure 2B). The results 
confirmed the strong interaction of Rb family proteins pRB, p107 and p130 
with E1A, as E1A co-immunoprecipitated all of these proteins (Figure 2B), 




Figure 2B. E1A co-immunoprecipitation of pRb proteins and CtBP. 
E1A protein was immunoprecipitated from HEK293 cell lysate using E1A 
monoclonal antibody M73. IgG was used as negative control. After isolation 
upon Protein G Agarose beads, immunocomplexes along with 10% input 
lysate were resolved on 10% SDS-PAGE and western blotted using primary 
antibodies, pRb (1:10), CtBP (1:10), p107 (1:500) and p130 (1:500), and 
appropriate horseradish peroxidase anti-species secondary antibody (Dako) 






C. In Vivo binding of Set1A and Set1B histone-directed 
metyltransferases to E1A. 
Previous work conducted in Dr. Turnell’s laboratory has indicated that there 
exists an interaction between H3K4 methyltransferases Set1A and Set1B and 
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Adv5 E1A, in both Adv5 E1-transformed cells and Adv5-infected cells (Munir 
and Turnell, unpublished observations). To confirm this I immunoprecipated 
Set1A and Set1B from Adv5 HEK293 and Adv12 HER2 cell lysates using 
rabbit polyclonal antibodies raised against Set1A and Set1B (Figure 2C). 
From the experimental results it was clear that both Set 1A and 1B interacted 
with E1A in vivo. In HER2 cells the interaction appeared to be stronger than in 
HEK293 cells especially using the Set1A 1420-1 and Set1B K1OB-1 
antibodies (Figure 2C). These data confirm previous observations that E1A 






     Figure 2C. Set1A and Set1B associate with E1A in vivo. 
Anti-Set1A, (741-1 and 1420-1) and Set 1B (K76A-2 and K1OB-1), antibodies 
were used for immunoprecipitation from HER2 cells, whilst Set 1A (741-1) and 
Set1B (K1OB-1) antibodies were used for immunoprecipitation from HEK293 
cell lysates. IgG was used as negative control. Imunocomplexes along with 
10% whole cell extract (WCE), as a positive control, were resolved on urea-
PAGE and western blotted for E1A using primary antibody M58 (1:2000) and 






D. E1A co-immunoprecipitates Set1A and Set1B from HEK293 cells. 
Given that I was able to show that Set1A co-precipitated E1A from HEK293 
and HER2 cells, I next  proceeded to determine if anti-E1A antibodies would 
co-immunoprecipitate Set1A and Set1B from these cells (Figure 2D). I 
therefore immunoprecipitated E1A from 293 cell lysates in HiLo buffer, using 
the M37 monoclonal antibody, and immunoprecipitated E1A from HER2 cells 
using a mix of the 163 and 170 monoclonal antibodies (Figure 2D). Consistent 
with co-precipitation of E1A with Set proteins (Figure 2C), I was able to co-
immunoprecipitate Set1A and Set1B from HEK 293 cells (Figure 2D). Both 
Set1A and Set1B were identified as two distinct bands upon SDS-PAGE 
(Figure 2D). Whether these bands correspond to different isoforms or reflects 
post-translational modifications awaits clarification. I was unable, however, to 
co-immunoprecipitate Set1A and Set1B from HER2 cells. Whether the inability 
of Adv12 E1A antibodies to co-immunoprecipitate Set proteins reflects the 
relative ability of these E1A antibodies to immunoprecipitate E1A, or that the 
Set binding site overlaps with the antibody epitope, requires further 
investigation. From the results presented in Figures 2C and 2D however, we 






Figure 2D. E1A associates with Set1A and Set1B in vivo. 
E1A was immunoprecipitated from HER2 cell lysates (using antibody 163 and 
170) and HEK293 cell lysates (using M37 antibody). IgG was used as 
negative control. After isolation upon Protein G agarose beads, both the 
immunocomplexes along with 10% WCE (whole cell extract), were resolved 
on 10% SDS-PAGE and western blotted for Set 1A and Set 1B using Set1A 
primary antibody, 741-1(1:2000) and Set1B primary antibody, K10B-1 
(1:2000). Horseradish peroxidase anti-rabbit secondary antibody was also 









3. E1A associates with histone H3- and H4- directed 
methyltransferase activities in vivo. 
Previous experimental work in the Turnell laboratory has shown that GST-Adv 
E1A 12S and 13S can immonoprecipiate histone H3- and H4- directed 
methyltransferase activities from A549 cells (Munir and Turnell, unpublished 
observations). To determine whether E1A proteins from HEK293 cells also 
associate with histone H3- and H4- directed methyltransferases, I performed a 
methyltransferase assay upon anti-E1A immunoprecipitates. Specifically, 
HEK293 cells were lysed in HiLo buffer and subsequently incubated with a 
number of different anti-E1A antibodies and antibodies raised against the S8 
component of the 19S proteasome (as a positive control). Following E1A 
immunoprecipitation upon Protein G agarose, IPs were incubated with 
radioactive adenosyl-L-[Methyl 3H]-methionine and core histones (H2A, H2B, 
H3 and H4) for 1.5 hours at 30˚C and the samples were resolved by SDS-
PAGE. The gel was then stained with coomassie, dried and exposed to X-ray 
film at -20ºC, and developed to analyse the methyltransferase activity 
associated with E1A (Figure 3). Results shows E1A associate with both 
Histone H3 and H4 directed methyltransferase activities and that the α-E1A 
antibody M37 was highly efficient, compared to the other α-E1A antibodies 
used in this study (Figure 3). S8 antibodies also co-immunoprecipitated both 
Histone H3 and H4 directed methyltransferase activities (Figure 3). From the 
results it can be concluded that E1A associates with functional histone-
directed methyltransferase activities in vivo, which might have implications for 








Figure 3. E1A associates with functional Histone-directed 
Methyltransferases. α-E1A antibodies M37, M58, M73, 610 and 611 (20 µg) 
were used to immunoprecipitate E1A from HEK293 cells. An antibody against 
the known E1A binding protein, S8, was used as positive control, and IgG was 
used as a negative control. Immunoprecipitates were isolated upon Protein G 
Sepharose beads for 2 hours at 4˚C, incubated with radioactive adenosyl-L-
[Methyl 3H]-methionine and core histones for 1.5 hours at 30˚C  and 
separated on 10% SDS-PAGE, stained with coomassie, dried and exposed to 
X-ray film. 
 
4. Set1A and Set1B associate with AdV early region 
promoters in AdV5-infected cells 
From the observations that Set methyltransferases can associate with Adv 
E1A in vivo, I next wanted to determine whether Set1A and Set1B can be 
found associated with E1A on early region gene promoters during w.t. Ad5 
infection. For this purpose I performed a Chromatin immunoprecipitation 
(ChIP) assay with anti- SET1A, Set1B and E1A antibodies from A549 cells 
which had been infected with w.t. Ad5 (1 p.f.u. /cell). 12 hours post-infection 
cells were treated with formaldehyde for 10 minutes and sonicated to shear 
the DNA; chromatin-DNA complexes were subsequently immunoprecipitated 
using antibodies against E1A (M58 and M73), Set1A and Set1B (Set 1A, 741-
1 and Set1B, K1OB-1) and IgG as a negative control. Immunoprecipitated 
viral DNA was recovered by ethanol precipitation followed by 
phenol/chloroform extraction and was analysed by performing PCR using 
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oligonucleotide primer pairs specific to E1A, E1B, E2e, E3 and E4 (Figure 4). 
From the results obtained it was interesting to see that E1A, Set1A and Set1B 
were all found associated with E1A, E1B, E2e, E3 and E4 promoters (Figure 
4). The E1A M73 antibody immunoprecipitated all of the early region 
promoters highly efficiently, whilst the M58 antibody co-immunoprecipitated 
E1B and E4 promoter elements, more efficiently than it did E1A, E2e and E3 
promoter elements (Figure 4). Set1A and Set1B was found to associate with 
E1A, E1B, E2e, E3 and E4 promoters, albeit at modest levels when compared 
to E1A (Figure 4). From the results presented however, it seems that Set1A 
and Set1B do regulate Adv early gene expression at the promoter level. It is 
also likely, that Set1A and Set1B recruitment to Adv5 early region promoter 








Figure 4. Recruitment of E1A, Set1A and Set1B to Ad early region gene 
promoters in vivo. 
Cross-linked chromatin, prepared from wt. Ad 5 [1 pfu/cell] infected A549 cells 
or uninfected “mock” cells, was immunoprecipitated with IgG, E1A [M58 and 
M73], Set1A or Set1B antibodies 12 hours post-infection. Following reversed 
of cross-links, phenol/chloroform extraction and ethanol precipitation, 
immunoprecipitated DNA was subjected to PCR analysis using primer pairs 
that corresponded to E1A, E1B, E2e, E3, E4 promoter regions. 
 
5. Investigating the role of Set1A and Set1B in viral early 
gene expression. 
After looking at the interactions of Set1A and Set1B with E1A, and 
determining that Set1A and Set1B associate with early region gene 
promoters, I wanted to investigate whether Set1A and Set1B were required for 
efficient early region viral gene regulation after the infection of A549 with 
Adv5. To do this A549 cells were treated with predesigned silencer select 
siRNA (Ambion) directed against Set1A and Set1B (or non-silencing controls) 
for 48h, and then infected with wild type Adv 5 at 1 pfu/cell for 4, 8, 16, 24, 32 
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and 48 hours. At these times post-infection cells were harvested, and protein 
concentration determined. Proteins were then resolved by SDS-PAGE and 
western blotted using antibodies for p53, SET1A and SET1B, as well as early 
region proteins, E1A, E1B-55K, E2A, E4Orf3 and E4Orf6 (Figure 5). 
Unfortunately, despite the guarantee from Ambion about the efficacy of the 
siRNAs, Set1A and Set1B knockdown was not successful (Figure 5). 
Therefore not surprisingly, there were no differences in the levels of the E1A, 
E1B-55K, E2A, E4orf3 and E4orf6 proteins (Figure 5). Unfortunately, 
therefore, no conclusions about the role of Set1A and Set1B in early region 






Figure 5. Investigating the role of Set1A and Set1B in viral early gene 
expression. 
A549 cells were transfected with siRNAs directed against Set1A and Set1B, or 
non-silencing controls and subsequently infected with Adv5. Cells were 
harvested at the appropriate times and protein concentration determined. 
Proteins were resolved by SDS-PAGE and the level of knockdown was 
assessed by western blotting with anti- Set1A and Set1B antibodies to 
determine knockdown efficiency. The whole cell extract was also analysed by 




6. Mass Spectrometry identification of E1A-binding proteins 
from HEK293 cells. 
After looking at the interactions of Set1A and Set1B with E1A, I found that the 
M37 E1A antibody was the most efficient for co-immunoprecipitation of Set1A 
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and Set1B, and association with active histone-directed methyltransferases. 
Therefore, I decided to perform mass spectrometry analyses upon anti-M37 
immunoprecipitates from HEK293 cell lysates to investigate whether I could 
identify novel E1A-interacting proteins. I therefore prepared HEK293 cell 
lysates using either stringent, HiLo buffer or, less stringent NETN buffer, and 
incubated lysates with E1A M37 or IgG, as a control. After isolation of the 
immunocomplexes upon protein G, I processed the immunoprecipitates for 
mass spectrometry (Refer to materials and methods section) Proteins that 
were found to associate with E1A in the HiLo buffer are presented in Table 1 
and Figure 6.1. Proteins that were found to associate with E1A in the NETN 
buffer are presented in Table 2 and Figure 6.2. The proteins in the tables 
highlighted in yellow shows previously identified E1A binding proteins; 
adenovirus E1A is highlighted in red. These data are summarized as string 
diagrams to show the relationship between the proteins identified (Figures 6.1 
and 6.2). In general more E1A-interacting proteins were identified in the less 
stringent NETN IP conditions compared to the more stringent HiLo IP 
conditions, although reassuringly a very similar set of E1A interacting proteins 
were identified. From the results obtained, some novel E1A interacting 
proteins were identified, like the MCM proteins, which are essential for pre 
replication complex formation and DNA replication. Proteins important for 
transcription and replication, like PRMT5, Fibrillarin and TIF1β were also 
identified. Despite the anti-E1A, M37 antibody being able to 
immunoprecipitate Set1A and Set1B from HEK293 cells, we did not identify 
these proteins in the mass spectrometry screen. This probably reflects the 




Protein    MW [kDa] Scores Peptides SC [%] 
CBP_HUMAN 265.2 786.0 (M:786.0) 20 9.7 
EP300_HUMAN 264.0 621.4 (M:621.4) 13 6.0 
E1BL_ADE05 55.0 584.4 (M:584.4) 12 30.0 
ELYS_HUMAN 252.3 538.0 (M:538.0) 13 8.0 
CTBP1_HUMAN 47.5 346.3 (M:346.3) 8 24.5 
ADT3_HUMAN 32.8 289.6 (M:289.6) 7 27.2 
IRS4_HUMAN 133.7 278.5 (M:278.5) 6 6.4 
E1A_ADE05 31.8 272.6 (M:272.6) 4 27.3 
ODPB_HUMAN 39.2 256.7 (M:256.7) 5 19.5 
PRKDC_HUMAN 468.8 251.7 (M:251.7) 7 2.4 
KPYM_HUMAN 57.9 240.5 (M:240.5) 5 13.2 
ADT2_HUMAN 32.8 228.2 (M:228.2) 6 18.5 
CTBP2_HUMAN 48.9 216.7 (M:216.7) 4 13.0 
DCAF7_HUMAN 38.9 216.4 (M:216.4) 6 26.0 
MCM7_HUMAN 81.3 210.9 (M:210.9) 6 11.8 
FBRL_HUMAN 33.8 195.2 (M:195.2) 5 17.8 
PRDX1_HUMAN 22.1 168.5 (M:168.5) 4 20.1 
ABCF2_HUMAN 71.2 166.2 (M:166.2) 4 8.3 
ATPO_HUMAN 23.3 149.0 (M:149.0) 3 21.1 
ZMY11_HUMAN 70.9 147.2 (M:147.2) 4 7.6 
HNRPU_HUMAN 90.5 146.5 (M:146.5) 3 5.5 
HNRH2_HUMAN 49.2 142.2 (M:142.2) 4 12.9 
PYRG1_HUMAN 66.6 141.7 (M:141.7) 3 6.4 
SENP3_HUMAN 65.0 132.7 (M:132.7) 2 4.9 
MCM6_HUMAN 92.8 129.3 (M:129.3) 3 5.6 
UBP11_HUMAN 109.7 114.6 (M:114.6) 3 3.3 
 
Table 1: Proteins identified in anti-E1A immunoprecipitates from HEK293 
cells isolated in HiLo buffer. 
HEK 293 cells were lysed in HiLo buffer (50mM Tris (pH 7.4), 0.825M NaCl, 
1% (v/v) NP-40) and subject to sonication and centrifugation. Supernatants 
were then incubated overnight with either 20 g normal mouse IgG (control), 
or 20 g of the anti-E1A monoclonal antibody, M37. Samples were 
subsequently incubated with 20 l of Protein G-Sepharose for 3h. The IPs 
were washed, denatured in 9M urea, 50mM ammonium bicarbonate and 
processed for mass spectrometric analysis as detailed in materials and 
methods section. Tryptic peptides were analysed using a Bruker Impact Time 
of Flight mass spectrometer, and identified using Proteinscape (Bruker) and 
the Mascot database (Matrix Science). The table shows proteins that 
specifically immunoprecipitated with the M37 antibody. Proteins highlighted in 
yellow represent previously identified E1A-binding proteins; adenovirus E1A is 







                       
 
Figure 6.1 String diagram showing proteins identified in anti-E1A 































Protein    MW [kDa] Scores   Peptides      SC [%] 
EP300_HUMAN 264.0 1360.2 (M:1360.2) 28 13.7 
CBP_HUMAN 265.2 1185.0 (M:1185.0) 26 14.0 
IRS4_HUMAN 133.7 502.3 (M:502.3) 10 9.9 
MCM7_HUMAN 81.3 494.1 (M:494.1) 13 25.7 
ACTG_HUMAN 41.8 484.2 (M:484.2) 8 33.1 
E1BL_ADE05 55.0 477.5 (M:477.5) 10 20.8 
HNRPM_HUMAN 77.5 471.7 (M:471.7) 12 20.1 
SHOT1_HUMAN 71.6 468.6 (M:468.6) 11 25.2 
HS90B_HUMAN 83.2 465.9 (M:465.9) 9 14.8 
ATD3A_HUMAN 71.3 459.9 (M:459.9) 11 19.2 
RB_HUMAN 106.1 432.7 (M:432.7) 8 10.1 
ATD3B_HUMAN 71.3 385.3 (M:385.3) 10 16.8 
E1A_ADE05 31.8 371.0 (M:371.0) 6 37.7 
ATPA_HUMAN 59.7 329.2 (M:329.2) 6 15.0 
KPYM_HUMAN 57.9 318.7 (M:318.7) 7 17.1 
ADT3_HUMAN 32.8 311.2 (M:311.2) 9 32.2 
CTBP1_HUMAN 47.5 305.3 (M:305.3) 7 24.1 
PRKDC_HUMAN 468.8 304.3 (M:304.3) 8 2.6 
ATPO_HUMAN 23.3 265.8 (M:265.8) 6 35.2 
COF1_HUMAN 18.5 263.4 (M:263.4) 6 48.8 
HS90A_HUMAN 84.6 238.4 (M:238.4) 5 8.7 
ODPB_HUMAN 39.2 226.0 (M:226.0) 5 19.5 
GBLP_HUMAN 35.1 223.5 (M:223.5) 5 18.0 
CH60_HUMAN 61.0 218.8 (M:218.8) 4 10.3 
HNRH1_HUMAN 49.2 209.3 (M:209.3) 5 16.7 
 
 
Table 2: Proteins identified in anti-E1A immunoprecipitates from HEK293 
cells isolated in NETN buffer. 
HEK 293 cells were lysed in NETN buffer (50mM Tris (pH 7.4), 0.25M NaCl, 
1% (v/v) NP-40, 1mM EDTA) and subject to dounce homogenization and 
centrifugation. Supernatants were then incubated overnight with either 20 g 
normal mouse IgG (control), or 20 g of the anti-E1A monoclonal antibody, 
M37. Samples were subsequently incubated with 20 l of Protein G-
Sepharose for 3h. The IPs were washed, denatured in 9M urea, 50mM 
ammonium bicarbonate and processed for mass spectrometric analysis as 
detailed in materials and methods section. Tryptic peptides were analysed 
using a Bruker Impact Time of Flight mass spectrometer, and identified using 
Proteinscape (Bruker) and the Mascot database (Matrix Science). The table 
shows proteins that specifically immunoprecipitated with the M37 antibody. 
Proteins highlighted in yellow represent previously identified E1A-binding 









Figure 6.2. String diagram showing proteins identified in anti-E1A 
immunoprecipitates from HEK293 cells isolated in HiLo buffer. 
http://string-db.org/ 
 
7. Validation of MCM interaction with E1A. 
Following the results obtained from Mass Spec, I carried out co-
immunoprecipitation studies with some of the E1A-interacting cellular proteins 
like the MCM proteins to validate the interaction. The mini-chromosome 
maintenance proteins (MCMs) are 6 structurally similar family of proteins 
MCM 2 to 7 which forms a hexameric complex which serves as an essential 
component of the pre replication complex that helps the replication origins to 
assemble during replication. 293 cell lysate in Hi Lo buffer was co-
immunoprecipitated with MCM 2 to 7 and the immunocomplexes were 
separated on urea-PAGE and western blotted for (Figure 7). From the results 
it was confirmed that MCM proteins interact with E1A. The functional 
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significance of this interaction requires further investigation. 
 
 
Figure 7.  MCM proteins associate with E1A in HEK293 cells. 
293 cell lysate was co-immunoprecipitated with MCM 2 to MCM 7 [MCM 7 
(Santa Cruz) and (Millipore)] and IgG was used as negative control. 
Imunocomplexes along with 10% whole cell extract (WCE), as a positive 
control, were resolved on urea-PAGE and western blotted for E1A using 
primary antibody M58 (1:2000) and horseradish peroxidase anti-mouse 


















Adenoviruses are typically used as a model system to investigate the role of 
viral early region proteins in the transcription of viral and cellular genes, and 
moreover, investigate the molecular basis of cellular transformation and 
tumourigenesis (Gallimore and Turnell, 2001; (Turnell, 2008). In this regard, 
Adv E1A has been studied in great detail to understand viral replication and 
cellular transformation as E1A associates with numerous cellular proteins that 
regulate transcription and function as tumour suppressor proteins. Adv E1A 
CR3 is very important for viral replication as it interacts with several cellular 
transcriptional factors, and transcriptional regulators, that serve to 
transactivate different cellular and viral promoters (Turnell, 2008). It has also 
been determined that the temporal regulation of transcription by E1A 
promotes the infected cell to enter the S-phase (Dery et al., 1985). The ability 
of E1A to regulate transcription programmes is achieved through its capacity 
to interact with factors that regulate transcription, such as: CBP/p300 (Co-
activators); pRB, p107 and p130 (repressors); CtBP (co-repressors); TBP and 
TAFs (basal transcriptional machinery); Sur2 (ancillary co-activators-
Mediator); and SWI and SNF (nucleosomal remodelling factors) (Gallimore, 
2001, Turnell, 2008). 
To understand fully the functional ability of Adv E1A to regulate viral gene 
regulation, it is important to identify specific, cellular binding partners that 
associate with the CR3 region of E1A, and then determine the consequences 
of the interaction upon transcription and viral replication. Interestingly, it is 
becoming clear that individual proteins serve as components of larger 
macromolecular complexes, and previous work in the Turnell laboratory has 
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determined the role of the proteasome and other CR3-associated proteins, in 
CR3-dependent transcription. Indeed, Rasti et al (2006) determined that 19S 
proteasomal ATPases, the 20S proteasome, and the 26S proteasome all 
interacted with CR3 of E1A to regulate viral transcription programmes. Later, 
unpublished work, conducted in this laboratory determined that the histone-
directed methyltransferases Set1A and Set1B bind to the CR3 domain of E1A. 
 
The primary aim of the present study was to investigate further the 
relationship between of Adv E1A and Set1A and Set1B in viral gene 
regulation. We initially started to investigate the specific roles of 12S and 13S 
E1A gene products in viral gene regulation following Adv infection. From the 
results obtained it was clear that CR3 was essential for E4 Orf6 and E4 Orf3 
expression (Figure 1.A), whilst E1B-55K and E2A expression was also mainly 
dependent on 13S E1A expression though 12S E1A also contributed towards 
their expression (Figure 1.A). Consistent with earlier studies my work 
confirmed the important role 13S E1A plays in transactivation. Presumably, 
the ability of 12S to transactivate the E1B-55K and E2A genes, resides in its 
capacity to interact with proteins such as the pRB family, CBP/p30, and other 
transcriptional regulators.   
 
To validate the functionality of E1A in HEK 293 cells, we next decided to 
investigate the ability of E1A to bind cellular proteins in these cells. To do this 
we immunoprecipitated the 293 cell lysate with antibodies specific for cellular 
proteins like CBP (N-terminal and CR1 binding protein), CtBP (C-terminal 
binding protein), pRB (CR1 and CR2 binding protein), p107 and p130 (CR1 
and CR2 binding protein) and TBP (Binding to N-terminus and CR3) and then 
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Western blotted for E1A. From the results, it was clear that E1A associates 
strongly with the pRB family of Pocket proteins, pRB, p107 and p130, when 
compared to C-terminal and N-terminal binding proteins CtBP, CBP and TBP. 
To confirm these results we performed reciprocal immunoprecipitations using 
anti-E1A antibodies. From the results obtained it was confirmed that all pRB 
family proteins interact with E1A in vivo. These pRB proteins acts as 
transcriptional repressors and normally serve to inhibit E2F-dependent 
transcription programmes; E1A interaction with pRB promotes pRB 
dissociation from E2F, which results in the activation of E2F-dependent 
transcription. E2F drives cell cycle progression, and inhibits cellular 
differentiation and tumour suppression (Gallimore and Turnell, 2001).  
 
After validating the functionality of E1A in HEK 293 cells, we investigated the 
interaction between the histone H3K4-directed methyltransferases, Set1A and 
Set1B and E1A in vivo. Previous work had determined that Set1A and Set 1B 
interact with Adv5 E1A, in both Adv5 E1-transformed cells and Adv5-infected 
cells (Munir and Turnell, unpublished observations). To confirm this, we 
immunoprecipitated Set1A and Set1B from Adv5 HEK 293 cell lysate, and 
Ad12 HER2 cell lysate, and resolved the immunocomplexes on an urea gel 
and Western blotted for E1A; we determined that Set1A and Set1B interacted 
with E1A in both Adv5- and Adv12- transformed cells (Figure 2C) and 
therefore confirmed the previous observations that E1A associates with Set1A 
and Set1B in vivo. It had not previously been determined however that Set1A 
and Set1B interact with E1A in Adv12-transformed cells. My data suggest that 
the interaction between E1A and Set1 proteins is conserved amongst 
divergent Adv types and that Set1 might play an important role in transcription 
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programmes regulated by different E1A species. 
 
After showing that Set1A co-precipitated E1A from HEK293 and HER2 cells, 
we next investigated whether anti-E1A antibodies co-immunoprecipitated 
Set1A and Set1B from these cells. Interestingly we was able to co-
immunoprecipitate Set1A and Set1B from HEK 293 cells, but not from HER2 
cells (Figure 2D). Set1A and Set1B were seen as two distinct bands upon 
Western blotting. Whether these bands correspond to different Set1A and 
Set1B isoforms, or reflects post-translational modifications needs to be 
clarified in future research.  E1A interacted with Set1A and Set1B in all my 
three experimental repeats from HEK 293 cells, and from the results obtained 
we confirmed both Set1A and Set1B methyltransferases interact with E1A in 
vivo and these interactions might play a crucial role in promoting E1A 
dependent transcription. We were unable to co-immunoprecipitate Set1A and 
Set1B from HER2 cells (Figure 2D). As we were able to perform the reciprocal 
co-immunoprecipitation in these cells, it is possible that the anti-Adv12 E1A 
antibodies used in this study sterically prevented the co-immunoprecipiation of 
the Set1 proteins. In the future it would be important to generate new Adv12 
E1A antibodies raised against different regions of the E1A protein and 
investigate whether they can co-precipiate Set1A and Set1B. 
 
It has previously been shown that GST-Adv E1A 12S and 13S can 
immonoprecipiate histone H3- and H4- directed methyltransferase activities 
from A549 cells (Munir and Turnell, unpublished observations). We therefore, 
investigated whether E1A associated with functional histone-directed 
methyltransferases in vivo in HEK 293 cells by performing a methyltransferase 
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assay upon anti-E1A immunoprecipitates. We demonstrated that a number of 
different α-Adv5 E1A antibodies could immunoprecipitate histone-directed 
methyltransferase activity from HEK 293 cells, and found that α-E1A antibody; 
M37 was highly efficient compared to positive control α-S8 (19S proteasomal 
ATPase) at immunoprecipitating methyltransferase activity (Figure 3). The 
reasons for this are not immediately apparent, but probably reflect the avidity 
of the M37 antibody for E1A, and the specific antibody-antigen binding site on 
E1A. From the results obtained we confirmed that E1A associates with 
functional histone-directed methyltransferase activities in vivo, which might 
have implications for the ability of 13S E1A to regulate viral transcription 
programmes. Interestingly E1A co-precipitated both H3 and H4 histone-
directed methyltransferase activity. As Set1A and Set1B are H3K4-directed 
methyltransferases it is not surprising that E1A co-precipitated H3 
methyltransferase activity. In the future it will be important to establish which 
H4 methyltransferases E1A can associate with, and determine whether they 
are important for E1A-regulated transcription. It will also be important to 
investigate whether AdvE1A can regulate site specific methylation of histones 
associated with cellular and viral gene promoters.  
 
Given these findings, we next proceeded to determine whether Set1A and 
Set1B associate with E1A on early region gene promoters. We performed a 
ChIP assay with antibodies against E1A, Set1A and Set1B. Interestingly 
Set1A and Set1B were recruited along with E1A to all the early viral promoters 
(E1A, E1B, E2e, E3 and E4) but at modest levels when compared to E1A 
(Figure 4). It is possible therefore that specific H3 K4 modification of 
chromatinized viral DNA at early region gene promoters by Set1A and Set1B 
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might facilitate transcription of viral genes. Therefore, from the data obtained 
we can speculate that Set1A and Set1B do regulate Adv early gene 
expression at the promoter level. It will be important in the future to determine 
whether the ability of Set1A and Set1B to interact with Adv5 early region gene 
promoters is dependent upon CR3. This could be achieved using Adv5 CR3 
mutants that do not bind to Set1A and Set1B. It would also be interesting to 
see whether antibodies that recognize mono, di and tri-methylated histone H3 
K4 can also chromatin immunoprecipitate early region promoters. This would 
establish further a role for Set1 proteins in E1A transcription programmes. 
 
To investigate a specific requirement for Set1A and Set1B in regulating CR3-
dependent transcription, we next attempted to knockdown Set1A and Set1B 
gene expression by siRNA and determine the consequences of knockdown 
upon the transcription of viral early genes following Adv5 infection. 
Unfortunately, the knock down was not successful in two experimental repeats 
(Figure 5). Due to lack of time I wasn’t able to investigate this further. In future 
research, therefore, it would be important to optimise Set1A and Set1B knock 
down using different clones of A549 cells, and then determine whether Set1A 
and Set1B expression in cells is essential for regulating early gene 
expression. It would also be interesting to see if general protein 
methyltransferase inhibitors, like 5′-deoxy-5′-methylthioadenosine (MTA) can 
inhibit Adv gene transcription. MTAs are known to inhibit histone 
methyltransferases such as Set1A and Set1B, and alter gene expression 
patterns (Huang et al., 2006). Indeed MTA has previously been shown to 
reduce the trimethylation of histone H3K4 associated with HSV-1 genomes, 
and furthermore inhibit HSV-1 viral gene expression and viral replication 
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(Huang et al., 2006). It might be, therefore, that Set1 proteins are common 
targets for DNA viruses. 
 
As we determined that the M37 E1A antibody was highly efficient in co-
immunoprecipitating Set1A and Set1B, and also associating with active 
histone-directed methyltransferases, we next decided to perform mass 
spectrometry analyses upon anti-M37 immunoprecipitates from HEK293 cell 
lysates to investigate whether we could identify novel E1A-interacting proteins 
(Figure 6.1 and Figure 6.2). Interestingly, some novel E1A interacting proteins 
were identified, like the minichromosome maintenance (MCM) proteins. 
MCMs are 6 structurally related proteins, MCM2 to MCM7, which form a 
hexameric complex and serves as an essential component of the pre-
replication complex during DNA replication to assemble the replication origins. 
Proteins important for transcription and replication, like PRMT5, Fibrillarin and 
TIF1β were also identified. We also determined that although the M37 
antibody was able to immunoprecipitate Set1A and Set1B from HEK293 cells, 
we couldn’t identify these proteins in the mass spectrometry analyses. This 
might be due to the greater sensitivity of western blots compared to mass 
spectrometry, or the failure to generate Set1 tryptic peptides of sufficient size 
and quality to be detected by the mass spectrometer.  
 
We next validated our mass spectrometry results by performing co-
immunoprecipitation experiments with MCM2 to MCM7 in HEK 293 cells to 
see whether E1A interacted with multiple MCMs in vivo. After resolving the 
immunocomplexes on a urea gel and western blotting for E1A, the results 
confirmed that E1A interacts with multiple MCM proteins in vivo. In future, 
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reciprocal immunoprecipitation should be performed to validate that E1A can 
immunoprecipitate MCM2 to MCM7 in vivo. Moreover, the biological 
significance of E1A interaction with MCM proteins should be investigated. 
Indeed, previous work has shown that, different DNA viruses target MCM 
proteins to inhibit host cell DNA synthesis in order to promote viral DNA 
replication (Roberts et al., 2008); HPV E4 represses cellular DNA synthesis 
through interacting with MCM2 and MCM7 and inhibiting the cellular origins 
required for replication, and likewise playing a prime role in viral replication 
(Roberts et al., 2008). From my results, we can hypothesize that the 
association of Adv E1A with MCM proteins, akin to HPV, could inhibit the 
origins of replication required for cellular DNA synthesis in order to enhance 
viral replication. It will be important to investigate this possibility. As MCM 
proteins also participate in transcription it will also be important to investigate 
their requirement for Adv transcription.  
 
In conclusion, work presented here has further defined E1A interaction with 
Set1 proteins, and established that Set1 proteins associate with viral early 
region promoters. Work presented here has also identified a number of 
potentially new E1A-interacting proteins, of which the MCM interaction with 
E1A has been validated. In the future it will be important to study the 
molecular roles of E1A-Set1 and E1A-MCM complexes, to see whether they 
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